The global direct-to-consumer genetic testing market is estimated to surpass $2,565.7 million by 2027, exhibiting a CAGR of 12.5% from 2020 to 2027.

The report aims to offer a clear picture of the current scenario and future growth of the global Direct-to-Consumer Genetic Testing market. The report provides scrupulous analysis of global market by thoroughly reviewing several factors of the market such as vital segments, regional market condition, market dynamics, investment suitability, and key players operating in the market. Besides, the report delivers sharp insights into present and forthcoming trends & developments in the global market.

The report articulates the key opportunities and factors propelling the global Direct-to-Consumer Genetic Testing market growth. Also, threats and limitations that have the possibility to hamper the market growth are outlined in the report. Further, Porters five forces analysis that explains the bargaining power of suppliers and consumers, competitive landscape, and development of substitutes in the market is also sketched in the report.

For More Detail Insights, Download Sample Copy of the Report at: https://www.researchdive.com/download-sample/504

The report reveals various statistics such as predicted market size and forecast by analyzing the major factors and by assessing each segment of the global Direct-to-Consumer Genetic Testing market. Regional market analysis of these segments is also provided in the report. The report segments the global market into four main regions including Asia-Pacific, Europe, North America, and LAMEA. Moreover, these regions are sub-divided to offer an exhaustive landscape of the Direct-to-Consumer Genetic Testing market across key countries in respective regions. Furthermore, the report divulges some of the latest advances, trends, and upcoming opportunities in every region.

Furthermore, the report profiles top players active in the global Direct-to-Consumer Genetic Testing market. A comprehensive summary of 10 foremost players operating in the global market is delivered in the report to comprehend their position and footmark in the industry. The report highlights various data points such as short summary of the company, companys financial status and proceeds, chief company executives, key business strategies executed by company, initiatives undertaken & advanced developments by the company to thrust their position and grasp a significant position in the market.

RESEARCH METHODOLOGY

The research report is formed by collating different statistics and information concerning the Direct-to-Consumer Genetic Testing market. Long hours of deliberations and interviews have been performed with a group of investors and stakeholders, including upstream and downstream members. Primary research is the main part of the research efforts; however, it is reasonably supported by all-encompassing secondary research. Numerous product type literatures, company annual reports, market publications, and other such relevant documents of the leading market players have been studied, for better & broader understanding of market penetration. Furthermore, medical journals, trustworthy industry newsletters, government websites, and trade associations publications have also been evaluated for extracting vital industry insights.

Connect with Our Analyst to Contextualize Our Insights for Your Business:https://www.researchdive.com/connect-to-analyst/504

KEY MARKET BENEFITS

KEY MARKET SEGMENTS

The global Direct-to-Consumer Genetic Testing market is segmented on the basis of the following:

Global Direct-to-Consumer Genetic Testing Market By Product Type:

Global Direct-to-Consumer Genetic Testing Market By Applications:

Global Direct-to-Consumer Genetic Testing Market By Regions:

Top Leading key players stated in Global Direct-to-Consumer Genetic Testing Market report are:

Ancestry, Color Genomics, Easy DNA, FamilytreeDNA (Gene By Gene), Full Genome Corporation, Helix OpCo LLC, Identigene, Karmagenes, Living DNA, Mapmygenome, MyHeritage, Pathway genomics.

The report also summarizes other important aspects including financial performance, product portfolio, SWOT analysis, and recent strategic moves and developments of the leading players.

Contact Us:

Mr. Abhishek PaliwalResearch Dive30 Wall St. 8th Floor, New YorkNY 10005 (P)+ 91 (788) 802-9103 (India)+1 (917) 444-1262 (US) TollFree : +1 -888-961-4454Email:[emailprotected]LinkedIn:https://www.linkedin.com/company/research-diveTwitter:https://twitter.com/ResearchDiveFacebook:https://www.facebook.com/Research-DiveBlog:https://www.researchdive.com/blogFollow us on:https://covid-19-market-insights.blogspot.com

Read this article:
Top Scenario: Direct-to-Consumer Genetic Testing Market 2020 to Witness Excellent Long-Term Growth Outlook Report by ResearchDive - The Think...

Recommendation and review posted by Bethany Smith

Play like you have this decision to make: Worldwide, in developed nations, people max out on average at 80 years. If you could have your life extended 40 years beyond that, would you go for it? Simply answer yes or no, please.

Genesis 6:3 might help. My spirit will not contend with humans forever, for they are mortal, it quotes the Lord. Their days will be a hundred and twenty years. Some scientists agree that 120 is about our limit.

Some doubt there is a life limit. So, lets add a scenario: What if you could choose to live forever? You go for that?

Is either 120 or immortality even possible? Answers: yes and maybe, well see.

Its yes because Jeanne Calment of Arles, France, lived to a now verified 122 years and 164 days. Jeanne stopped smoking at 117, but never gave up her nightly port wine. She took up fencing at 80 and bicycled into her 100s. When asked on her 120th birthday what she expected from the future, she said, I expect a short one. Jeanne was born in 1875 and died in 1997.

Many scientists use Calments age as sort of a doable goal for extending life. According to Woody Allen, You can live to be 100 if you give up all the things that make you want to live to be 100. But 100 aint 120. And Woodys quip doesnt answer whether we can end The End for humans. Could other species shed light?

Some species might suggest there is no life-limit. Tortoises live to 255; an invertebrate Quahog clam clocked in at 507; Greenland shark, 512; and one bristlecone pine dubbed the Methuselah, is 4,852 years old. But according to Aging Research Reviews as reported in National Geographic, the winner is a deep-sea sponge. Age: at least 11,000 years.

So, whats up? Human age is up. This year, the United Nations expects the number of centenarians, worldwide, to exceed 573,000. For perspective, eight years ago, the United Nations estimated that there were only 316,600 living centenarians worldwide.

But beyond 100, Mother Nature hits the brakes. The number of supercentenarians, those making it into the 110 club, though not known for sure, is estimated to be about 600, worldwide.

What is known is that as of Oct. 21, there were 50 supercentenarians (18 from the U.S. and 11 from Japan; 90 percent female.) The aging curve changes between 100 and 110.

According to British actuary Benjamin Gompertzs predictions, the mortality rate for adult humans roughly doubles every additional eight years. However likely you are to die in 2020, youll be twice as likely in 2028, four times as likely in 2036. The death curve goes up like that, sharply till 100.

So, while reaching 100 is still unlikely at present, if you do reach it, things begin looking up. The sharpness of Gompertzs mortality curve flattens out at about 100.

Some scientists have explained that the deceleration of the death rate beyond 100 could suggest that there is no fixed limit to the human lifespan.

Traditionally, aging has been viewed as inevitable as death. But what if age isnt inevitable, but a curable disease? What about death then?

British gerontologist Aubrey de Grey, chief science officer at a California research foundation, says aging is not unavoidable, its simply a medical problem that science can solve. While de Grey does consider life extension a health issue eliminating age-related diseases like cancer, stroke, Alzheimers, heart disease, etc. he views it from different lenses.

Treating and beating age-associated diseases has always been approached discreetly. Tackle this, tackle that. But thats precisely because aging has never been regarded as a disease. If it were, and were conquered, then age-associated diseases would no longer exist. Win-win.

David Masci, a researcher for Pew Research Center, says life extension is no longer the realm of cranks and science fiction writers. Heavy hitters are pouring serious money into tackling aging at its root.

From 1997 to 2013, Oracle co-founder billionaire Larry Ellison contributed $45 million annually to his Ellison Medical Foundation, which focuses on the aging process while simultaneously lowering and eliminating age-related diseases.

Ellison stopped contributing in 2013 because Google founded California Life Co., which seeks to reverse-engineer the biology that controls lifespan and devise interventions that enable people to lead longer and healthier lives essentially Ellisons goal.

Life extension approaches vary, from ways to eliminate decrepit (senescent) cells, to pursuing Metformin, the closest now to a drug that appears to target aging, to extrapolating from discovery that a single-gene mutation doubles the lifespan of certain roundworms.

So maybe well see. Meanwhile, remember that Lucille Ball said, The secret of staying young is to live honestly, eat slowly, and lie about your age.

Michael Smith is a Southern Pines writer.

Follow this link:
Column: Just How Old Is 'Old Age' in The Future? - Southern Pines Pilot

Recommendation and review posted by Bethany Smith

Global Oral Probiotics market report 2020 offers extremely oblique professional analysis and forecast from 2020 to 2026. The report also consists of market shares, size, profit revenue, and the Oral Probiotics markets economic process. It also covers the strategic identification of major players within the market and analyzing their core competencies and methodology. The Oral Probiotics market report analyzes information collected and integrated through recent analysis techniques and from trustful sources across varied industries.

A thorough evaluation of the restrains encompassed in the Oral Probiotics report reveals the difference to drivers and contributes room for strategic planning. Features that overshadow the Oral Probiotics market development are essential. They can be understood to devise different bends for getting hold of the profitable prospects present in the ever-growing market. Additionally, perceptions by market expert opinions have been taken to understand the Oral Probiotics market better.

[Due to the pandemic, we have included a special section on the Impact of COVID 19 on the market which would mention How the Covid-19 is Affecting the Global Oral Probiotics Market]

Get a Sample Copy of this Report @https://www.futuristicreports.com/request-sample/53001

Top Key Players of Oral Probiotics Market:

(Oragenics, Life Extension, TheraBreath, Lallemand, Bluestone Pharma, Jarrow Formulas, Now Foods, BioGaia, ProBiora Health, Hyperbiotics, Bifodan)

On the basis of Types, the Oral Probiotics market:

Powder Chewable tablets Others

On the basis of Applications, the Oral Probiotics market:

Child Adult

To Understand How Covid-19 Impact Is Covered in This Report With additional Discount: https://www.futuristicreports.com/check-discount/53001

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2016-2026) of the following regions are including,

The Research aims of the Oral Probiotics Market report would be:

Major TOC points

1Oral Probiotics Market Overview

1.1 Product Overview and Scope of Oral Probiotics

1.2 Segment by Type

1.2.1 Global Sales Growth Rate Comparison by Type (2021-2026)

1.2.2 Type 1

1.2.3 Type 2

1.3 Segment by Application

1.3.1 Sales Comparison by Application: 2020 VS 2026

1.3.2 Application 1

1.3.3 Application 2

1.4 Global Market Size Estimates and Forecasts

1.4.1 Global Revenue 2016-2026

1.4.2 Global Sales 2016-2026

1.4.3 Oral Probiotics Market Size by Region: 2020 Versus 2026

2 Global Oral Probiotics Market Competition by Manufacturers

2.1 Global Sales Market Share by Manufacturers (2016-2020)

2.2 Global Revenue Share by Manufacturers (2016-2020)

2.3 Global Average Price by Manufacturers (2016-2020)

2.4 ManufacturersOral Probiotics Manufacturing Sites, Area Served, Product Type

2.5 Market Competitive Situation and Trends

2.5.1 Oral Probiotics Market Concentration Rate

2.5.2 Global Top 5 and Top 10 Players Market Share by Revenue

2.5.3 Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.6 Manufacturers Mergers and Acquisitions, Expansion Plans

2.7 Primary Interviews with KeyOral Probiotics Players (Opinion Leaders)

3 Oral Probiotics Retrospective Market Scenario by Region

3.1 Global Oral Probiotics Retrospective Market Scenario in Sales by Region: 2016-2020

3.2 Global Oral Probiotics Retrospective Market Scenario in Revenue by Region: 2016-2020

3.3 North America Market Facts and Figures by Country

3.4 EuropeOral Probiotics Facts and Figures by Country

3.5 Asia Pacific Market Facts and Figures by Region

3.6 Latin America Market Facts and Figures by Country

3.7 the Middle East and Africa Market Facts and Figures by Country

4 Global Oral Probiotics Historic Market Analysis by Type

4.1 Global Sales Market Share by Type (2016-2020)

4.2 Global Revenue Market Share by Type (2016-2020)

4.3 Global Price Market Share by Type (2016-2020)

4.4 Global Market Share by Price Tier (2016-2020)

5 GlobalOral Probiotics Historic Market Analysis by Application

5.1 Global Sales Market Share by Application (2016-2020)

5.2 Global Revenue Market Share by Application (2016-2020)

5.3 Global Price by Application (2016-2020)

..Countinued

Inquire or Share Your Questions If Any before the Purchasing This Report https://www.futuristicreports.com/send-an-enquiry/53001

Our Other Reports:

Murumuru Butter Market by Production Demand, Consumption, Top Regions and Covid-19 Impact by 2026 | Natural Products, Jarchem Industries, Natural Sourcing and Others

Electric Hand Warmer Market Trend, CAGR Status, Forecast and Covid-19 Impact by 2026 | Zippo, Fourheart, Letouch and Others

Compression Fitting Market Analysis, Size, Share and Covid-19 Impact by 2026 | Pegler Yorkshire, FIP, Brennan and Others

Lipstick Market Size, Trends Research Report and Covid-19 Impact by 2026 | LOreal, MAXFACTOR, CHANE and Others

Futuristic Reports

Name: Mark RiveraTel: +1-408-520-9037Email: [emailprotected]

Continue reading here:
Oral Probiotics Market Outlook, Global Key Players and Covid-19 Impact by 2026 | Oragenics, Life Extension, TheraBreath and Others - TechnoWeekly

Recommendation and review posted by Bethany Smith

Some of the best sci-fi movies are layered and complex, while others are confusing beyond belief and demand several rewatches to unravel it all.

Science fiction movies are often meant to be somewhat complicated, and the fanbase is typically made of people who want something challenging they can appreciate. While the movies need to be visually entertaining and raise viewers' emotions, they also need to play to the tropes of the genre to succeed and have long-lasting success.

RELATED:10 Classic Science Fiction Novels That Need A Film Adaptation

However, some science fiction movies have fans scratching their heads in confusion and many of these movies require a second viewing to figure things out. The best science fiction movies award this second viewing with clues placed throughout the film to make it a satisfying experience.

In 2010, Christopher Nolan created one of his top critically acclaimed movies with the mind-bender,Inception. The film stars Leonardo DiCaprio as a thief who steals information using technology that allows him to enter a person's subconscious to gain access to memories that help the companies hire him.

He is offered a chance to erase his criminal past if he implants another person's memories into someone else's head. Despite its complicated premise, it was a huge success and won four Oscars.

Duncan Jones is the son of the late rock-star, David Bowie, but he set out to make his name as a filmmaker without riding the coattails of his father's more famous name.

While he is known for his bigger movies, includingSource Code and Warcraft, he made his debut with what might be his best film,Moon. The movie was shot with a small budget, with Jones doing all the effects. The movie stars Sam Rockwell, a man on a moon mission alone who starts to see visions right before he is set to return home.

Christopher Nolan was back in 2014 with another confusing movie, this one a sci-fi film called Interstellar. When it comes toobscure and complexplot points,Inceptionis child'splay compared to Interstellar's messages and themes.

The movie stars Matthew McConaughey as a man who lives on a future Earth where people struggle to survive. He then joins a group of astronauts who travel to a wormhole by Saturn and end up finding a lot more than they ever dreamed of.

In 2001, Donnie Darkowas the movie that made Richard Kelly the next big thing. The sci-fi movie was so great that Kelly could never live up to its promise afterward. Part of the reason for this was that Kelly tried to re-up the confusing storylines from this first film with the ultra-confusing Southland Tales.

RELATED:10 Sci-Fi Films Even People Who Hate Science Fiction Will Love

Jake Gyllenhaal starred in Donnie Darko as a teen who starts to have doomsday visions. By the end, viewers realize nothing in the movie is as it seemed and a rewatch shows how Donnieunderstood his fate.

Primer is widely considered one of the smartest sci-fi movies ever made. It is also extremely confusing and requires a rewatch to catch everything the filmmakers are trying to convey.

Directed by Shane Carruth, Primer is a movie with a complex and nonlinear plot that uses complex technical dialogue and philosophical science fiction theories. The film is about the accidental discovery of time travel, and it deals with alternate timelines in a very complicated manner.

Released in 2007, the Spanish-language science fiction film Timecrimes confused and enthused fans everywhere.

In this movie, a man named Hector finds himself trapped in a non-stop time loop, and as time goes on, more and more of his selves pop up in the world from the future, and he does what he can to stop these anomalies from appearing. This is yet another time-travel movie that takes multiple watches to piece everything together.

Darren Aronofsky is a director that has made several complicated and intellectual indie-style movies. His first two critically acclaimed movies, Pi and Requiem for a Dream, both tackled complicated subject matter in a way that was very polarizing for some viewers. The Fountain took it to another level.

RELATED:Top 10 Female Protagonists in Science Fiction Movies

Hugh Jackman and Rachel Weisz star in this movie about love and loss of love across three different timelines. It has a touch of fantasy and spirituality, and its hardcore sci-fi storylinemeans there is no way to understandit without watching it two or more times.

Solaris is based on a science fiction novel written in 1961 by Stanislaw Lem about scientists at a research station trying to understand extraterrestrial intelligence on an alien planet.

There were two iterations of this film, the first coming in 1972 by Andrei Tarkovsky and the second in 2002 by Steven Soderbergh. Both are complex films that deal with the scientists' emotional crisis as they try to understand the unknown.

Stanley Kubrick directed one of the seminal sci-fi movies in history with 2001: A Space Odyssey. The film is about a group of people aboard a spacecraft on a trip to Jupiter, alongside a sentient computer named HAL to investigate the possibility of alien life.

When everyone dies except for one person, Dr. David Bowman, he continues the journey with HAL, but soon realizes that HAL might have nefarious plans of its own. By the end, Bowman is having visions and is transforms into a fetus - needless to say, the film requires another watch or two to understand what just happened.

In 2001, Cameron Crowe directed the remake of the 1997 Spanish-language film Open Your Eyes. RenamedVanilla Sky, the movie stars Tom Cruise as a man involved in an accident who wakes up to find his face disfigured.

Penelope Cruz and Cameron Diaz co-star as two women involved in his life, but as he tells his story to a psychologist (Kurt Russell), it appears something has happened to him that he doesn't remember. It all goes off the rails when a company specializing in "life extension" comes into the picture.

NEXT:The 10 Best-Looking Science Fiction Shows Of All Time

Next 10 Best Films That Were Mostly Set In Or Underwater, Ranked According To IMDb

Shawn S. Lealos is a freelance writer who received his Bachelor's degree in Journalism from the University of Oklahoma with a minor in Film Studies. He has worked as a journalist for over 20 years, first in the world of print journalism before moving to online media as the world changed. Shawn is a former member of the Society of Professional Journalists and the Oklahoma Film Critics Circle before relocating to Texas and has work published in the Daily Oklahoman, Oklahoma Gazette, Vox Magazine and Loud Magazine and on websites like The Huffington Post, CBS, Time Warner Cable, Yahoo, The Movie Network, Chud, Renegade Cinema, 411mania and Sporting News. Shawn is also a published author, with a non-fiction book about the Stephen King Dollar Baby Filmmakers and has begun work on a new fiction series as well. Visit Shawn Lealos' website to learn more about his novel writing and follow him on Twitter @sslealos.

Read more here:
10 Sci-Fi Movies That Only Make Sense On A Rewatch | ScreenRant - Screen Rant

Recommendation and review posted by Bethany Smith

Feminizing hormone therapy is a common way for transfeminine or gender non-binary individuals to achieve traditionally female characteristics and feel more comfortable in their own bodies. Here's how it works, what you can expect from the procedure, and important health risks to know.

Feminizing hormone therapy can involve taking estrogen and anti-androgen hormones. An anti-androgen is any drug that blocks the production of male sex hormones, mainly testosterone.

"We're increasing estrogen levels while also decreasing testosterone levels," says Ravi Iyengar, MD, an endocrinologist at Rush University Medical Center with a clinical expertise in transgender medicine.

Ultimately, the target is to lower the patient's testosterone levels to that of the typical cis female range, which is around 30 to 100 ng/dl. The following medications are usually used:

"I usually talk to most of my patients that, in general, hormone therapy is not quick to act. It's a process and it does take a couple of years," Iyengar says.

Here is a general timeline and description of the changes you might expect from feminizing hormone therapy:

Shayanne Gal/Insider

To develop the right individualized treatment plan, you should talk with your doctor about what you'd like to gain from feminizing hormone therapy and your preferred timetable, as you can adjust your dosage accordingly.

The lower your dose of feminizing hormones, the slower the changes you'll see in your body. However, this doesn't necessarily mean that higher doses cause faster changes, and they may even endanger your health.

In fact, high doses of estrogen can increase the risk of blood clots, stroke, and estrogen-related tumors, according to a 2018 study. That's why preliminary blood tests are important for those seeking to go on feminizing hormone therapy.

"Every person is unique based on their own health factors and their family history," says Amy Weimer, MD, a primary care physician with a clinical interest in transgender care at UCLA Health. "But at the very baseline, we typically check blood count and a liver and kidney panel, then may check tests for cholesterol or diabetes or occasionally hormone levels as well."

Blood clots are the best characterized risks for estrogen therapies, says Joshua Safer, MD, an endocrinologist at the Center for Transgender Medicine and Surgery at Mount Sinai Hospital. However, they're not common. A 2017 study found that blood clots form within roughly two of 1,000 people on feminizing hormone therapy.

Those taking spironolactone must also know their baseline potassium levels. Spironolactone is known as a potassium-sparing diuretic, meaning it prevents the body from having low potassium levels. The drug blocks the hormone aldosterone, which causes the kidneys to pass fluid while keeping potassium.

In some cases, potassium could build up to higher than normal levels in a condition called hyperkalemia, though it is also rare.You should check in with your doctor if you experience the following symptoms of hyperkalemia:

Weimer also says there are a few medical cases where feminizing hormone therapy may be more harmful to your health, such as having signs of breast cancer, colorectal cancer, or any cancer sensitive to estrogen.

While feminizing hormone therapy comes with some health risks, for some people, not receiving this treatment can be even more harmful. "It is, for many people, a life-threatening condition to continue without access to hormone therapy," Weimer says. "It carries its own very high health risk."

To find an expert well-versed in transgender care, try to find a WPATH provider near you. WPATH stands for World Professional Association for Transgender Health and aims to promote evidence-based care, education, research, public policy, and respect in transgender health. Other good places to look for a provider include LGBT centers, community health centers, or community clinics, says Weimer.

See original here:
Feminizing hormone therapy: Medications, effects, and risks - Insider - INSIDER

Recommendation and review posted by Bethany Smith

Studies have advised avoiding strenuous exercise at least one hour before bedtime.

Staying awake in bed

Weve all experienced it at one point or another: lying awake in bed at night staring at the wall. Experts say doing that can be harmful down the road.

If you dont fall asleep within 20 minutes of going to bed, get up, go to another room and do a calming activity, then go back to bed," Dr. Guy Leschziner, a consultant neurologist at the sleep disorder center, Guys and St. Thomas' hospitals in London told The Guardian. "If you are lying in bed unable to sleep, your brain will soon start associating lying in bed with being awake.

Drinking alcohol

You may have heard of sipping a nightcap before bed, but experts warn against having one containing alcohol.

Some people end up self-medicating with a nightcap, because it does help them to fall asleep more easily at the beginning of the night," Stacey Gunn, sleep medicine physician at the Insomnia and Sleep Institute of Arizona, told HuffPost. "But I recommend against it because it causes the sleep architecture to be disrupted later on, resulting in poor quality sleep.

Consuming caffine

Much like drinking alcohol before bed, experts dont consume the stimulating drug before getting some shut-eye.

If you have caffeine later in the day, it can actually predispose you to develop insomnia or make it worse if you already have it, Dr. Rachel Salas, an associate professor of neurology at Johns Hopkins Medicine who specializes in sleep medicine, told Self magazine.

Still, its important to note that recent studies have indicated that drinking coffee before bed may not be as bad as other pre-sleep habits, such as using nicotine or drinking alcholic beverges.

Using their phones or laptops sans blue light filter

Researchers have noted that blue light from cellphones and TV screens can delay the production of melatonin the hormone that regulates the sleep-wake cycle in the body.

Checking your phone stimulates the brain so we are more active and awake, Cleveland Clinic sleep disorder specialist Dr. Harneet Walia told Health Essnetials. Even just a quick check can engage your brain and prolong sleep.

Read this article:
Experts say they avoid these 5 things before bed - Atlanta Journal Constitution

Recommendation and review posted by Bethany Smith

A study presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting identified sexual dysfunction as a treatment side effect experienced by the majority of cancer survivors that is not currently well addressed.1

Further, female survivors were significantly less likely to have their sexual dysfunction addressed. Researchers suggested that these collective findings demonstrate the utility of using validated sexual health questionnaires for both male and female cancer survivors to improve physician engagement and facilitate open discussion between patients and providers to improve the quality of life of cancer survivors.

Sexual dysfunction is an unfortunately common side effect of cancer treatment, and there appears to be a large gender disparity in how physicians discuss sexual health with their patients, lead author James Taylor, MD, MPH, chief resident in radiation oncology at the Sidney Kimmel Cancer Center at Thomas Jefferson University in Philadelphia, said in a press release.2 "Our results show that we are asking men about sexual dysfunction caused by cancer treatment, but we are not asking women as frequently. We should be asking everyone, to determine how we can help."

An IRB-approved questionnaire developed with input from radiation oncologists, medical oncologists, and surgeons was administered from 2017 to 2019 on social media and in clinic using an iPad. The survey was compromised of more than 25 questions and was directed specifically to cancer survivors. However, patients with missing data were excluded from the study analysis.

In total, 405 cancer survivors responded to the survey and 391 (96.5%) were included in the analysis. The majority of respondents were female (n = 313; 81.0%), between the ages of 41 and 50 years old (n = 115; 30.0%), and typically had cancer types such as breast (66.8%) or pelvic tumors including prostate (16.3%), endometrial (6.1%), bladder (3.8%), and rectal (1.8%) cancer. In total, 47.4% of patients received anti-hormone therapy, 78.1% received chemotherapy, and 54.2% received radiation therapy.

Overall, 44% of respondents reported they were preemptively told that sexual health could be affected. Moreover, the majority (n = 337; 87%) of respondents indicated that cancer treatment impacted their sexual function or desire, with 53.8% reporting body image distortion, 73.4% with dyspareunia, and 42.3% unable to achieve orgasm.

Only 27.9% of respondents stated they had been formally asked about their sexual health from a provider. Additionally, male patients were significantly more likely to have been asked than female patients (53% vs. 22%, P < .001). Specifically, standardized sexual health questionnaires were administered to 31.5% of male cancer survivors and only 5.4% of female cancer survivors (P = .001), though 51% of all patients reported that they would be most comfortable with the conversation about sexual health to be initiated by their provider after being given a questionnaire to stimulate that conversation.

"Patients seem to prefer completing a survey or questions about their sexual health in clinic and then reviewing this information with their provider, rather than the physician directly asking the patient or the patient driving the discussion," Taylor explained. "A questionnaire administered to all patients can reduce uncomfortable feelings and make bridging the discussion much easier. We know that validated instruments exist, and it is time to put them into practice."

Of note, response bias may have influenced the high rates of sexual side effects observed in this study. Moving forward, the investigators intend to collect additional responses to validate their findings and include a wider variety of cancer types, combining their results with a companion survey of oncologists that asks similar questions on sexual health discussions from the provider perspective. The researchers also plan to conduct pilot studies that implement existing questionnaires in the clinic to determine where additional tools are needed.

References:

1. Taylor J, Ruggiero M, Maity A, et al. Sexual Health Toxicity in Cancer Survivors: Is There a Gender Disparity in Physician Evaluation and Intervention? Presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting. Abstract #: 1042.

2. Sexual health often overlooked in cancer survivorship care, especially for female patients [news release]. Arlington, Virginia. Published October 27, 2020. Accessed November 2, 2020. https://www.astro.org/News-and-Publications/News-and-Media-Center/News-Releases/2020/Sexual-health-often-overlooked-in-cancer-survivors

More here:
Sexual Dysfunction Not Well Addressed in Female Cancer Survivors - Cancer Network

Recommendation and review posted by Bethany Smith

Dopamine and serotonin are both neurotransmitters chemical messengers that transmit signals between cells which regulate bodily functions like mood, sleep, and digestion.

While dopamine and serotonin have similar effects on the body, they work a bit differently. Here's what you need to know about the similarities and differences between dopamine and serotonin.

"While it does not precipitate the pleasurable experience, dopamine does serve to reinforce the pleasurable experience," says Kristin M. Stover, PsyD, a licensed psychologist in Florida and telehealth specialist with AristaMD, a telehealth provider.

Advertisement

Because dopamine is related to the reward system and reinforces pleasurable experiences, it is thought to play a role in addiction and compulsive gambling, though researchers aren't yet sure of the exact link between dopamine and these behaviors.

Meanwhile, low levels of serotonin can have the opposite effect and negatively impact your mood. Low levels of serotonin have been linked to depression as well as sleep and appetite disturbances, Stover says.

Serotonin also regulates important bodily functions. For example, your gut, which houses 90% of the body's total serotonin, releases chemicals when you eat to stimulate your intestines and move food through your digestive system. Blood platelets also release serotonin when you get a cut or scrape to heal wounds.

Serotonin and dopamine do not function independently of one another. Instead, they work together to create complex patterns of behavior.

"When one neurotransmitter is altered, there is a change in the function or prevalence of the other substance," Stover says. "Increased levels of serotonin can lead to decreased dopamine activity and vice versa."

Because both dopamine and serotonin affect mood, they are thought to play a role in mood disorders like depression. For example, researchers have observed decreased levels of serotonin in people with depression and other types of mental illness, like anxiety and attention deficit hyperactivity disorder (ADHD).

"Because serotonin is responsible for sleep, mood, and digestion, we often see symptoms of depression that reflect that imbalance, such as sleeping too much or too little, having no appetite or overeating," Stover says.

Long-term or chronic stress can also lead to elevated cortisol levels a hormone released as a stress response. High levels of cortisol reduce the production of both serotonin and dopamine and have been linked to depression, says Nicole Avena, PhD, an assistant professor of neuroscience at Mount Sinai Medical School and a visiting professor of health psychology at Princeton University.

"Targeting the dopamine system is one of the ways in which we can look at potential mechanisms and treatments for depressive behaviors," Avena says.

More here:
Serotonin vs. dopamine: A guide to the two mood-regulating hormones and how they can affect your health - Business Insider India

Recommendation and review posted by Bethany Smith

About the Authors:Ian Chiangis aprincipal atFlare Capital Partners, a healthcare technology and services-focused VC firm. Prior to joining Flare, he was the SVP of product and innovation and a founding member of Cignas CareAllies. Previously, he was a digital health entrepreneur and a former management consultant at McKinsey & Company.

Poorwa Godbole is an MBA candidate at the Wharton School concentrating in Health Care Management and a Flare Capital Scholar. Prior to Wharton, she was a management consultant at McKinsey & Company focused on health systems and services and a member of the Health & Life Sciences team at Gates Ventures. She is a graduate of Stanford University.

Disclaimer:Flare Capital Partners is an investor inBright Health, Eden Health and Iora Health.

HIMSS20 Digital

Healthcare delivery has undergone unprecedented changes in the past decade. Over the past five to 10years, healthcare's digitization has accelerated exponentially due to innovative government policies, changes in consumer preferences, an influx of venture capital, a growing number of digital health entrepreneurs and continued investments by industry incumbents.

The COVID-19 crisis has highlighted some of the challenges in our healthcare system and presented unique opportunities for the U.S. healthcare system to innovate in real time. Across the board, we have seen healthcare providers adopt telehealth at an unprecedented rate. While the last chapter of COVID-19s impact on the evolution of our healthcare delivery system is far from being written, we would like to highlight 10 major care-delivery trends accelerated by COVID-19.

Telemedicine (or telehealth) is not a novel concept. (See thehistory.)Yet adoption was slow for both patients and providers in the early years. The COVID-19 crisis has ushered in unprecedented changes and made virtual health more mainstream. During the early days of COVID-19, numerous primary care providers across the U.S. were forced to shut down their physical facilities. As a result of this sudden shock, many aggressively adopted and rolled out telehealth. In some cases, advanced primary care groups, such as Iora Health, converted almost all care to a virtual setting.

Because of our value-based payment model and team-based delivery model, we were able to do the right thing when [COVID-19]hit quickly pivot to doing over 90% of our encounters by phone and video, and proactively reach out all of our patients over the first few weeks and many times thereafter, reminding them to stay distanced and wear masks, Rushikia Fernandopulle, Iora Healths CEO, said.

Similarly, Privia Health, a network of 650 provider practices, quickly scaled its existing telehealth capabilities.

Telehealth was a priority at Privia even before COVID-19, Shawn Morris, CEO at Privia Health, said. We invested in building our own solutions. We did 400,000 plus virtual visits in the early days of COVID-19, including 60,000+ unique senior visits. About 20% of our patient encounters are done virtually, and we can certainly do more.

Most health systems have also observed a surge in virtual visits (e.g., Ochsner sees nearly 1000% increase in virtual visits in March 2020).

While not all primary care practices were equipped with internally developed technologies to scale telemedicine operations rapidly, many were able to adopt SaaS platforms, such as doxy.me. Despite the range in readiness found across providers, Bain & Company reports that by April 2020, 97% of primary care physicians were using telemedicine to treat patients, primarily for non-COVID-19 or nonurgent care.

Its likely no coincidence that this acceleration in demand for virtual health closely preceded a new annual record for digital health funding led by mega deals in virtual care delivery (e.g., AmWells nearly $194M Series C round in May and eventual IPO in September). Though the huge jump in demand for virtual care dropped in recent months as the country opened up, many care delivery organizations are still seeing significant utilization of virtual health and expect at least one-fifth to a quarter of patient encounters to be done virtually going forward (See John Halamkas interview).

For providers, Telehealth is a great tool to help doctors provide better care, enhance the patient experience and expand panel size and access, Morris said.

While virtual primary care will not replace 100% of in-person care visits, we believe that the primary care delivery landscape will be profoundly changed going forward,due to the increased adoption of virtual health and acceleration toward value-based reimbursement.

Because of Ioras value-based business model, when the pandemic hit, our revenue did not change one bit due to the shift to virtual care, Fernandopulle said. For years traditional practices have claimed they have been trying to operate in both the fee-for-service and value worlds at the same time with one foot on the dock and the other in the canoe. What [COVID-19] has shown is that the dock is now on fire so its time to get both feet in the canoe and start paddling!

Like primary care, a large portion of specialty care has also shifted to virtual delivery during the COVID-19 pandemic. However, the expected permanence of these virtual models will vary by specialty.

On one end of the spectrum, there are procedure-based specialties that cannot exist solely digitally. (See Telehealth usage as percent of total visits by specialty)For instance, many procedures in specialties like ophthalmology and orthopedics have been delayed due to a temporary ban on elective surgeries during the early months of COVID-19 (e.g., one study estimated a backlog of one million-plus cases for spinal fusions and joint replacements in the field of orthopedic surgery alone).

These surgical procedures will return in the post-pandemic world, and while we do not anticipate procedures being done virtually, we foresee a shift towards increasingly virtual preoperative and postoperative consultations.

On the other end of the spectrum, we saw an accelerated movement of some specialties or subspecialties into the virtual world. In recent months, we have seen many digital health companies that offer ongoing care and management of specific conditions or diseases (e.g., hair loss, sexual health, migraine, sleep andbehavioral health conditions) enjoy rapid growth.

For example, Thirty Madison has a full process in place for diagnosing a patients hair-loss condition, creating a treatment planand sending a treatment supply directly to the patient without any in-person interaction. AbleTo, Talkspace, Lyra Health, Octave Health, Mindstrong and others offer virtual therapy, coaching and digital measurement for mental health support. During COVID-19, these companies have provided patients with much-needed specialty care, while their brick-and-mortar peers were forced to shut down temporarily.

Reliance on virtual care solutions for behavioral health continues to be high as of October 10, when in-person visits to behavioral health providers were still 14% below pre-pandemic levels. On top of their commercial traction, these virtual specialty care providers have shown that they can raise mega-funding rounds during the height of COVID-19 (See:Mindstrong announces$100 million funding, Lyra raised $110 million Series D fundingandCerebal lands $35M). We believe these strong commercial and financial tailwinds will lead to the creation of a new generation of virtual specialty care providers.

Additionally, we see a rise in uptake of virtual specialty care-enablement platforms. For example, Heartbeat Health is the developer of a telemedicine and virtual care platform for cardiologists. Technology platforms like Heartbeat Health were vital during the pandemic, which caused 75% of cardiology outpatient encounters to shift to telehealth within just two weeks.

The use of these tools across the country has demonstrated how virtual delivery can increase access to care, improve efficiency and patient satisfaction, and provide a more personalized and coordinated experience. Virtual health-enablement platforms in other specialties (e.g., Babyscripts in OBGYN) have also flourished.

"Payers and ACOs are looking closely at radically reducing costs in high-prevalence, high-cost conditions like [cardiovascular disease]. Many will seek Virtual First players who are willing to go at sub-risk," Dr. Jeff Wessler, CEO of Heartbeat Health, said.

The movement from fee-for-service to fee-for-value will also serve as a tailwind for the rise of virtual specialty care providers or enablement platforms.

Furthermore, the emergence and incorporation of virtual specialty care will likely be hyper-charged in the post-pandemic world. Digital health behemoths, like Teladoc and Livongo, are joining forces to accelerate the development of an integrated, full-stack specialty care platform. In itsS4 filing, Livongo highlighted the potential for the merged company to create the next generation of specialist care offering both medical specialty care and chronic-condition-management services in a combined, remote solution that augments standard care.

Across primary care and specialty care, we see providers beginning to use an increasing mix of synchronous and asynchronous delivery. Some types of asynchronous care (e.g., forwarded X-rays or MRIs to be interpreted by a radiologist) are well established. But with the shift towards more virtual care, other types of asynchronous communication, such as text and media messages, are increasing in utilization, both for patients to consult with their physicians and forphysicians to consult with other specialists.

Asynchronous care delivery amplifies telemedicine's benefits and increases patients access to low-cost, high-value care. For instance, a patient requiring non-emergent care for a skin rash can now send a photo to her primary care provider. Instead of commuting to the doctor's office, spending time in the waiting roomand only getting a few minutes with the physician, the patient can now go about their day at home and take the appropriate steps when the provider replies asynchronously.

The use of asynchronous care also increases provider efficiency. Physicians can now see a full panel of patients in person without limiting their ability to provide virtual care. The asynchronous nature of the visit allows physicians to respond to requests at their convenience.

This also creates opportunities for quality improvement. Physicians have more time to gather a patients full history and data, research hypotheses and consult with others before responding to a patient. Providers can also see all the patient data in a structured, standardized format, allowing them to potentially complete three to six visits in the time it would take to do one synchronous visit. Companies likeZipnosisare taking advantage of asynchronous care and "store-and-forward"solutions to improve both the patient and the provider experience.

While asynchronous care delivery is growing, a synchronous chat or text is simultaneously emerging as a dominant model. Some synchronous chat applications (e.g., KHealthand98point6) combine artificial intelligence with physician expertise. Patients begin by chatting with a bot to discuss symptoms and get an initial diagnosis.

If needed, a physician will then chat with the patient live to discuss next steps or prescribe a care plan. These synchronous chat applications are becoming more and more popular (e.g., 98point6 raises $118 million) and integrated with other providers. In September, Sams Club announced a collaboration with 98point6 to provide members discounted subscriptions to the text-based app and virtual visits for just $1.

While some pundits are concerned about the quality of synchronous text/chat-based and asynchronous care, a study at Stanford Health Care has shown asynchronous teledermatology to be effective in increasing access and maintaining high-quality care. Companies like hims, Alpha Medical and Thirty Madison are already putting these results to use and creating a physician-patient experience that is centered on chat or text.

Eden Health, which offers virtual-first primary care and onsite clinics to employers, is experiencing the rise in demand for asynchronous and synchronous virtual care during the pandemic.

Medical problems are rarely solved in a single experience, so we see messaging interactions continuing to increase as patients get exposure to its ease and effectiveness, Matt McCambridge, CEO at Eden Health, said. Combining the convenience of messaging with the power of face-to-face video appointments in a single application creates a seamless and positive experience for our patients,

As millennials and Generation Z become more engaged healthcare consumers, we believe that synchronous and asynchronous interactions will continue to gain prominence as the preferred mode of engagement, especially in primary and low-acuity specialty care.

According to a PWC Health Research Institute survey, 38% of large employers offered an onsite health clinic in 2019, up from 27% in 2014. Just as these numbers are rising, the COVID-19 pandemic has caused many companies to operate with a primarily remote workforce. Though working from home may become part of the new normal, employees will still expect easily accessible and affordable care from employers.

Healthcare is no longer viewed only as an employee benefit.Its now a necessity for maintaining a strong workforce, McCambridge said. With a large percentage of employers now embracing liberal work-from-home policies, access to healthcare for distributed workforces is critical. This mindset shift has accelerated demand for virtual primary care, and interest in our telemedicine solution from employers has surged by more than 500% since the beginning of the outbreak in March.

To meet this demand, employers will need to explore virtual care delivery options. Incumbent employer/work-site health providers (e.g., Marathon Health, Premise HealthandCigna Onsite Health) have adopted or expanded virtual health during COVID-19. Other well-known employer-focused medical groups with 24/7 virtual capabilities have seen significant growth in membership. (One Medical saw a 25% increase in year-over-year membership growth in Q2 2020.)In addition to virtual-first solutions, employers and commercial health plans are actively exploring ways to extend care, especially urgent and emergency care, to employee/members homes. (See Trend 8.)

Whether partnering with a virtual-first employer health-solution provider, expanding telehealth benefits or adding home-based care delivery options, employers across the U.S. (and around the world) are actively looking to meet their employees healthcare needs in a multimodal fashion.

In the wake of the pandemic, many prominent hospital systems are using virtual encounters to provide safer and timely care. For instance, at theUniversity of Pennsylvania Health System, telehealth is being used across the board to understand a patients symptoms and let them know if they need to visit the ER, reduce ICU interaction and provide therapy over the phone.Systems and government agencies have rapidly adopted AI symptom checkers (e.g.,GYANT,Ada,BabylonandBuoy Health) to improve patient experience and to handle increased volume in a cost-effective manner.

For example, Intermountain Healthcarejointly developeda COVID-19 Screener and Emergency Response Assistant (COVID-19 SERA) with GYANT and rolled it out in April of 2020. Intermountain has seen a30% decreasein call center volume, which frees up patient-clinician communications for those who need it most. Other health systems have also adopted similar tools.(See:Montefiore using HyroandSyllable.AI powering New York Presbyterians COVID-19 web bot.)

While we are still in the early innings of AI-based triage, and more complex clinical algorithms will need to be developed to facilitate smarter triage, there is no doubt that AI-based triage tools will play a significant role in changing the way healthcare providers will evaluate and direct patients to the most appropriate site of care going forward.

Providing healthcare in rural areas is challenging on multiple dimensions large elderly populations with multiple comorbid conditions, many uninsured patients and lack of specialists. Many providers already operate at a loss, which has deepened during the pandemic when elective procedures (which typically make up half of a hospitals revenue) were canceled or delayed.

According to the Texas Commissioner of Rural Health, 60 of the 163 rural hospitals have less than 30 days of cash on hand. Some of these facilities are looking to telehealth solutions to stay connected to patients during this time. (See:Ballad Health announces major expansion of virtual health program to lower cost and improve urgent care access.)

As we look forward to the role that telehealth will play in primary care in rural areas, we believe the adoption of virtual health will be further accelerated by innovative funding models (e.g.,CHART) from the Centers for Medicare & Medicaid Services (CMS) Innovation Center.

COVID-19 will also have a lasting impact on access to specialty care. Platforms like RubiconMD and AristaMD that connect primary care doctors with specialists for eConsults help to improve access to specialty care in rural areas, where wait times for referrals to see a specialist could be exceedingly long.

Rural medicine is facing a shortage of over 20,000 physicians, a resource strain that has only intensified with the global pandemic, CEO of RubiconMD Gil Addo said. It's more important than ever to empower PCPs in rural areas to provide the most comprehensive care possible. eConsults through RubiconMD allow these doctors to receive same-day insights from specialists across the country, improving care and saving patients unnecessary appointments and the often long, burdensome and costly trips that go along with them."

Going forward, we believe there will be an increased demand for eConsults in both outpatient and inpatient settings, especially at rural facilities where access to specialists is limited.(See:Avail raises $100Mfor telemedicine in the operating room.)We also believe that virtual primary care will be more ubiquitous in rural areas.

While there is still a digital divide between rural and urban areas, the Federal Communication Commission (FCC) has moved aggressively to expand broadband access across America. We anticipate that additional funding will increase broadband and high-speed wireless Internet access in rural America in the post-COVID-19 world and further accelerate the adoption of innovative virtual health services.

With healthcare facilities reaching capacity, patients fearing contracting illness from entering a doctors office, and with high-risk patients needing to stay away from others, COVID-19 has everyone thinking about the future of care delivery in the home. Though providing care virtually removes the human touch from medicine, it also enables a physician to see a patients home environment and potentially discover factors affecting a patients health that may not be obvious when examining the patient in the office.

In addition to basic virtual visits, RPM technologies (e.g., TytoCare, Current Health, Vivify Health, Harmonize Health, AliveCorandEko) and home-based point-of-care diagnostic (POC Dx) tools (e.g., Scanwell Health) allow clinicians to actively examine or passively monitor their patients.

Prior to COVID-19, CMS expanded the reimbursement of RPM services in its final rule on Chronic Care Remote Physiologic Monitoring in November 2019. Increased adoption of value-based care, and providers taking on the financial risk of managing chronically ill patients, haveled to increased investment in RPM solutions. According to one study from 2019, 88% of providers surveyed have invested or are evaluating investments in RPM technologies. Even telecom giants like Comcast are riding these tailwinds. (See:Comcast's launch of Quil Health for RPM for aging seniors.)

Payment reforms, adoption of value-based care payment and COVID-19 subsidies will undoubtedly usher in integration of traditional telemedicine, RPM and home-based POC Dx. In a podcast conversation with Senator Bill First, Dr. Eric Topol a renowned cardiologist and author predicts we will soon be in a Telemedicine 2.0 world where patients can actually collect and share health data with their physicians in order to receive care at home. The merger between Teladoc and Livongo may foreshadow what is yet to come.

During the height of the COVID-19 crisis in many states, we witnessed an overwhelming demand for hospital beds for critically ill patients, and many hospitals converted various wards into ICUs. As a result of an actual or anticipated surge in need forhospital beds for COVID-19 and other severely ill patients, many health systems around the country have accelerated their efforts to stand up hospital-at-home (HaH) programs to provide hospital-level care in the patients home. (See:Intermountains Castell launched its HaH programMayo launched advanced care at home model of care.)

In the post COVID-19 world, it is more important than ever to provide hospital-level care to high-risk patients directly from advanced primary care settings.

The hospitals of the future will expand virtually into homes to provide appropriate acute-level care, Rajesh Shrestha, Castell president and CEO and Intermountain VP and COO for community-based care, said. Intermountain Healthcare and Castell Health launched this new service to support patients who are at risk for hospitalization or complications.

Additionally, COVID-19 has exposed the downside of relying on fee-for-service revenue for many health systems. In the aftermath of COVID-19, we anticipate health systems to take on a more aggressive approach when it comes to value-based contracts and securing more reliable payments from health plans (e.g., Allina, BCBS of Minnesota announced a six-year value-based contract in August of 2020).

As hospitals are beginning to invest more in HaH programs, we are also seeing elevated demand from patients for receiving healthcare services in the comfort and safety of their homes in a post-COVID-19 world. While we have seen the rapid adoption of telehealth by providers and patients, telehealth is undoubtedly not the be-all and end-all solution to comprehensive care. Invariably, there are true urgent or emergent cases that would require a clinician to provide an in-person examination of patients.

House call companies (e.g., DispatchHealth, RemedyandHeal) that equip mobile care teams with equipment needed to perform high-acuity medical care will see an increase in demand from patients. Health plans and risk-bearing entities (e.g., self-insured employers) will look to accelerate rolling out of house calls to prevent unnecessary ER utilization, which could often lead to in-patient admissions. Many of these new house call companies are also integrating telemedicine services to shorten turnaround time and improve the patient experience.

Furthermore, COVID-19 will have a lasting impact on some of the most chronically ill patients' willingness to receive in-person care. Anecdotally, we have heard many primary care physicians, including ones from advanced primary care groups, highlight that some Medicare Advantage (MA) or Medicaid patients refused office-based visits even as states opened up. Home-based care delivery or home-based primary care will become even more important going forward for MA health plans and risk-bearing providers to close care gaps.

In 2013, Cigna acquired Alegis Care, a Chicago-based house call company, to provide chronic care management for severely ill, homebound Medicare and Medicaid patients. Humana recently made a $100 million investment in Heal, and highlighted the investment and partnership as part of their efforts to build a broader set of offerings across the spectrum of home-based care. Similarly, Landmark Health has provided home-based primary care, house call, and telemedicine services since 2013.

COVID-19 will accelerate home-based care delivery and drive integration of various home-based care delivery services across the acuity continuum.

The crisis has demonstrated how health disparities and risk-levels for a disease are impacted by income, geography, race and other factors. Experts have been pointing out the importance of acknowledging and addressing social determinants like food or housing insecurity as part of a patients care plan for years, but social spending in the U.S. is still low. Now, with entire cities needing to take steps like finding housing for homeless populations, awareness of social determinants of health (SDoH) is rising.

We have seen organizations rapidly ramp up their efforts in providing holistic care to patients and helping risk-bearing providers integrate SDoH screening, coordinationand tracking as part of their workflows. Companies like UniteUs, Healthify, NowPow, AuntBertha and others have seen an elevated demand from payers and providers.

Integrated delivery networks have long been champions of SDoH. (See:Intermountain pours $12M into social determinants of health efforts in 2018, Geisingers Fresh Food FarmacyandKaiser Permanente launched initiatives that will improve health outcomes by creating stable housing for vulnerable populations.)Health plans are also ramping up on their SDoH efforts. (See:Centene makes investments to combat hunger, improve connectivity and provide key health and educational products to those in need during COVID-19.)We continue to be hopeful that this elevated awareness will be durable post-COVID-19.

The COVID-19 pandemic has increased public awareness of the inequality that exists in the U.S. healthcare system and the differences in healthcare access and outcomes across population groups. Astudy of telemedicine cardiology careat the University of Pennsylvania found that patients who completed video visits with their providers "were slightly older, more likely to be male, less likely to be Black, and had a higher median household income than patients who completed telephone-only visits."

For marginalized groups like racial and ethnic minorities, studiesshowmistrust of providers may be amplified in virtual settings due to limited communication and providers being less mindful of implicit bias. For other groups, like transgender people, especially those in rural areas, virtual care may be the solution to raising the quality of and access to gender-affirming care.

While today's brick-and-mortar healthcare system has often underinvested in care-delivery solutions for historically overlooked communities, we see digital health companies leading the way to creating population-specific solutions for underserved groups (e.g., Medicaid, women, BIPOC, LGBTQ andrural communities).

Maternal health innovators (e.g., Quilted HealthandBabyscripts) are working to provide much-needed services to women who have inadequate prenatal care access. On the BIPOC side, companies like Cityblock Health are bringing interdisciplinary teams including primary care providers, behavioral health specialists, pharmacists, nurse care managers and social workers to communities where they are needed most. Other early-stage innovators, such as Juno Medical, are looking to build next-generation primary care providers in neighborhoods overlooked by One Medical and other commercially focused providers.

Ethnically focused next-generation primary care and multi-specialty care providers (e.g., Asian-focused andLatino-focused) and Independent Physician Associations (IPAs) partnering with next-generation health plans with ethnically-focused care programs (e.g., Bright HealthandClever Care) will emerge in years to comeas many ethnically-focused care-delivery entities have delivered superior quality and outcomes. (See:LEON Medical Centers Health Plans awarded a five-star rating by Medicare for the third time in 2020.)

Another historically overlooked community with population- and sub-population-specific health needs is the LGBTQ community. Over the past few years, we have seen advancements led by digital health companies. Companies such as Plume Health are expanding access to gender-affirming hormone therapy.

Others, like Queerly Health and Included Health, help match LGBTQ patients with healthcare providers. Other platforms are emerging (e.g., Folx Health, which raised venture funding in August 2020).

As healthcare delivery is becoming more population-specific and personalized, we predict that there will be a proliferation of population-specific in-person and/or virtual care innovators focusing on the needs of historically underserved communities.

Originally posted here:
Zooming into the next phase of care delivery: 10 emerging trends in a post-COVID-19 world - Mobihealth News

Recommendation and review posted by Bethany Smith

Its been a very challenging time. The coronavirus. The election. Now winter is coming. White Plains Hospital has some tips for navigating Seasonal Affective Disorder.

For many, the shortening, colderdays can signify many months of depression. If you feel despondent the same time every year, you could be suffering from Seasonal Affective Disorder (SAD).

There is more to SAD than the acronym implies. Seasonal Affective Disorder is a form of depression that lasts for four or five months until the days become longer again. This disorderaffects an estimated 10 million Americansand women are four times more likely to be diagnosed with it than men.

Researchers have found that people with SAD produce too much melatonin, a hormone that regulates sleep. A persons circadian rhythm, or body clock helps determine their sleep patterns, says Dr. Christopher Robles, a Family Medicine and Primary Care physician at White Plains Hospital. When theres less lightand particularly when the seasons change your body clock signals to the brain to make more melatonin so you get drowsy. Body clocks that run fast or slow can disrupt your sleep.

SAD signs

People with Seasonal Affective Disorder often develop a predictable set of signs and symptoms, which may include:

How to stop feeling SAD

There is evidence thatthe amount and quality of sleep we get is associated with the amount of vitamin D our bodies absorb, particularly in the colder months. Fortunately, Dr. Robles says, a natural source of this vitamin is readily available. You can get vitamin D from sunlight, so go outside, even if its just during your lunch break, she says It can have a positive effect on your mood.

A healthy diet can also help chase away that SAD feeling. Dr. Robles recommends eating natural foods like egg yolks, mushrooms, fatty fish and liver because theyre full of vitamin D and nutrients.

Finally, staying active can help your body and mind settle into a more restful routine. Exercising for 30 minutes three times a week can help boost your mood and relieve stress and anxiety.

Nearly everyone has days when they feel lethargic or down, and thats normal. But if you feel down for days at a time and you cant get motivated to do activities you normally enjoy, see your primary care physician. They will be able to analyze your symptoms and help you get back to a healthier state.

Dr. Christopher Roblesspecializes in Family Medicine and Primary Care and sees patients at the Somers and White Plains practices. To make an appointment, call914-849-7075.

The rest is here:
How to Fight SAD in Challenging Times - theLoop

Recommendation and review posted by Bethany Smith

There's a variety of bread out there to choose from, but two of the most common types are white bread and whole wheat bread. While they are both made from grains, there are key health differences between the two types of bread due to the way that they're made.

Here's what you need to know about the differences between white bread and whole wheat bread, as well as which one is healthier for you.

Whole wheat bread contains more nutrients, but white bread may be fortified with vitamins: Since 100% whole wheat bread has all three components of the grain, it typically has a higher nutritional value than white bread. This is because the bran and the germ have richer concentrations of vitamins and minerals than the endosperm.

Advertisement

Plus, the germ contains:

For example, a major supermarket brand's white bread may have 120 calories, whereas their 100% whole wheat option may have around 100 calories. Specific calorie differences will vary based on brands.

Whole wheat bread has more fiber: Another nutritional difference between white bread and whole wheat bread is that whole wheat bread has more fiber. White bread usually contains about 1 gram or less of dietary fiber per serving, and 100% whole wheat contains around 3 or 4 grams of dietary fiber. Again, specific values will vary brand by brand.

White bread may be a better choice if you have digestive issues: "Eating 100% whole wheat bread is a healthier option for most people unless you are having a flare-up of a GI condition, such as Crohn's disease, ulcerative colitis, gastroparesis, and diverticulitis or are suffering from diarrhea, then you may need to follow a lower fiber diet and choose more refined grains," says Pence.

This is because some GI conditions are aggravated by high-fiber foods, causing further GI discomfort. For example, if you have diarrhea, having a lot of fiber in your diet may further increase the frequency of stools.

Read more here:
Why 100% whole wheat bread is usually a healthier choice than white bread - Business Insider India

Recommendation and review posted by Bethany Smith

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a pioneering genomic diagnostics company, announced that the Federal Joint Committee (G-BA) has approved its Prosigna Breast Cancer Gene Signature Assay. The G-BA decision to reimburse the Prosigna test will provide access to the test for all breast cancer patients in Germany with HR+/HER2- early-stage breast cancer.

The Prosigna Assay is a second-generation breast cancer test, meaning that it uses advanced genomic technology combined with clinical and pathologic features to inform next steps for patients with early-stage breast cancer. The test analyzes the activity of 50 genes known as the PAM50 gene signature, along with tumor size, lymph node involvement, and a tumor proliferation score to provide early-stage breast cancer patients and their physicians with a prognostic score indicating the probability of cancer recurrence during the next 10 years.

We are pleased with the G-BA decision, which will enable more breast cancer patients and their physicians in Germany to benefit from the genomic insights offered by our Prosigna test, said Bonnie Anderson, chairman and chief executive officer of Veracyte. Further, because Prosigna is performed by laboratories locally, this decision will enable German laboratories to deliver precision medicine solutions directly to their physician customers.

The Prosigna test is recommended in guidelines from the German Association of Gynecologic Oncology (AGO), as well as the European Society for Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO) and the National Institute for Health and Care Excellence (NICE) in the United Kingdom.

Every year around 70,000 women in Germany develop early breast cancer. In many cases, a clear therapy recommendation for or against adjuvant chemotherapy is challenging based on the clinicopathological criteria alone. The Federal Joint Committee supports the use of biomarkers, now including Prosigna, to inform treatment decisions based upon the patients individual cancer recurrence risk.

About Prosigna

Prosigna is a prognostic Breast Cancer Gene Signature assay indicated in female breast cancer patients who have undergone either mastectomy or breast-conserving therapy in conjunction with locoregional treatment consistent with standard of care, either as a prognostic indicator for distant recurrence-free survival at 10 years in post-menopausal women with Hormone Receptor- Positive (HR+), lymph node-negative, Stage I or II breast cancer or lymph node-positive (13 positive nodes, or 4 or more positive nodes), Stage II or IIIA breast cancer to be treated with adjuvant endocrine therapy alone, when used in conjunction with other clinicopathological factors.

In addition to the risk of recurrence (ROR) information, in Europe the assay provides the intrinsic subtypes of the tumor tissue within three groups low, intermediate and high. The tests performance is validated for use on the nCounter Analysis System in laboratories across Europe.

About Veracyte

Veracyte (Nasdaq: VCYT) is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The companys growing menu of genomic tests leverage advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The companys tests in thyroid cancer, lung cancer, breast cancer and idiopathic pulmonary fibrosis are available to patients and its lymphoma subtyping test is in development. With Veracytes exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide. For more information, please visit http://www.veracyte.com and follow the company on Twitter (@veracyte).

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, our statements related to our plans, objectives, expectations (financial and otherwise) or intentions with respect to Veracytes Prosigna Breast Cancer Gene Signature Assay for use in predicting long-term risk of recurrence among breast cancer patients. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will" and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. Examples of forward-looking statements include, among others, statements regarding Veracytes belief that its Prosigna Breast Cancer Gene Signature Assay helps physicians accurately predict long-term risk of recurrence among breast cancer patients. These statements involve risks and uncertainties, which could cause actual results to differ materially from our predictions, and include, but are not limited to: Veracytes ability to achieve and maintain reimbursement coverage for its tests; the continued inclusion of its tests in recommendations of medical associations and agencies; the benefits of Veracytes tests and the applicability of clinical results to actual outcomes. Factors that may impact these forward-looking statements can be found in Item 1A Risk Factors in our Annual Report on Form 10-K filed with the SEC on February 25, 2020 and in our Quarterly Report on Form 10-Q filed with the SEC on November 2, 2020. A copy of these documents can be found at the Investors section of our website at http://www.veracyte.com. These forward-looking statements speak only as of the date hereof and Veracyte specifically disclaims any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.

Veracyte, Afirma, Percepta, Envisia, Prosigna, LymphMark, and the Veracyte logo are trademarks of Veracyte, Inc.

Read more here:
Prosigna Breast Cancer Assay Now Approved for Reimbursement in Germany - Business Wire

Recommendation and review posted by Bethany Smith

Modern life has brought numerous dangers, as the environment is significantly polluted, and toxins and dangerous substances may threaten our wellbeing. Our health is greatly affected by the food and drinks we consume.

Water is of critical importance, so we are all advised to drink at least two liters of filtered water during the day. Moreover, we should avoid greasy, sugary, and salty foods, and focus more on natural and organic fruits and vegetables.

However, most of you are not aware of the consequences of the use of plastic containers. Namely, the companies that produce foods and beverages are more concerned about their financial profit, than the production of healthy and safe products for their customers.

Therefore, it is of high importance to learn the meaning of the labels on the bottom of plastic bottles, as they indicate the extent to which they are harmful.

Plastic bottles are constantly around us, as we often buy water bottles when we go to work when we go for a walk, we buy water for our children in school, we get several of these water bottles when we go on a trip, and so on.

However, these bottles are significantly harmful to our health, and this is indicated by the triangle found onevery bottles bottom.

This plastic is a far better option than many others, as it is not likely to release chemicals into the water and it is usually used for making the plastic containers of certain food products.

This plastic type is also safe, and it is usually white or transparent. It is used in the production of containers of syrups and yogurt.

This plastic type releases cancer-causing mixes, as well as metals, antimony, and EPA synthetic substance, which intervenes with the hormone capacity.

PVC releases two dangerous elements, whose combination affects the hormonal capacity. It is the most commonly used plastic in the production of bottles.

This kind of plastic discharges STYRENE inside the water, which is a dangerous cancer-causing substance. It is often used in single-use coffee glasses and fast-food containers.

It discharges the concoction BPA and it is undoubtedly the most dangerous one. PC is commonly used in the production of sports bottles, nourishment stockpiling, as well as baby food containers.

To conclude, only the first two types of plastic, PP and HDPE, are not dangerous to your health, as they do not release harmful chemicals into the water.

On the other hand, the use of the other plastic types can seriously endanger your health, so in order to prevent their harmful consequences, it is advisable to use only glass water bottles.

On the other hand, the use of the other plastic typescan seriously endanger your health,so in order to prevent their harmful consequences, it is advisable to use only glass water bottles.

This is not intended to be a substitute for professional medical advice. Always seek the advice of your physician or other qualified health care professional.

Source: http://www.healthyfoodadvice.net

Continue reading here:
Plastic The Sillent Killer Check What Is Written At The Bottom Of The Plastic Packaging - johnscreekpost.com

Recommendation and review posted by Bethany Smith

If you've taken an over-the-counter pain reliever before, you've likely had aspirin or ibuprofen. These are both very common nonsteroidal anti-inflammatory drugs, or NSAIDs, that are typically used to treat pain, inflammation, and fevers.

They are popular active ingredients in various brand name products such as Advil and Motrin (ibuprofen) or Bayer and Ecotrin (aspirin). However, just because they are over-the-counter, it doesn't mean that they come without risks or are safe for everyone to use.

Aspirin is made out of salicylic acid, and ibuprofen is made from propionic acid. The difference between the two acids is due to their chemical structures, particularly where the carbon and oxygen are located.

Advertisement

"When we inhibit those prostaglandins, we inhibit that inflammatory cascade of reactions which is what is causing pain. So, we eliminate the inflammation, or, reduce inflammation, and with it goes the pain as well," says Medhat Mikhael, MD, pain management specialist and medical director of the non-operative program at the Spine Health Center at MemorialCare Orange Coast Medical Center in Fountain Valley, California.

Mikhael says for some chronic pain conditions, ibuprofen may be taken long term during flare-ups, as long as they "interrupt" the doses and take a week or two off from the medication. Ibuprofen is more suitable than aspirin for longer-term use in situations like this.

Overall, Mikhael says they can both be used to treat the same problems, including:

Your doctor may recommend that you take daily baby aspirin if you are at high risk for heart attack or stroke, like if you have very high blood pressure or have had a heart attack before.

As with most medications, aspirin and ibuprofen both run the risk of side effects, including serious ones. Some potential side effects include:

But unlike aspirin, ibuprofen may increase your risk of cardiovascular problems. This is why it's so important to use medications as directed and only short term, not long term, to avoid these serious side effects.

The following groups of people may want to avoid ibuprofen due to the increased risk of related side effects:

More here:
Aspirin vs. ibuprofen: The key differences and which one you should take - Business Insider India

Recommendation and review posted by Bethany Smith

PRESS RELEASE:3 November 2020, 07:00 CET

Biocartis and GeneproDx To Collaborate on Fully Automated ThyroidPrint test on Idylla

Mechelen, Belgium, 3 November 2020 Biocartis Group NV (the Company or Biocartis), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces it has signed a license, development and commercialization agreement with GeneproDx, a molecular diagnostics company based in Santiago, Chile, for the development of GeneproDxs novel genomic test ThyroidPrint on Biocartis rapid and easy to use molecular diagnostics platform Idylla.

Under the terms of the agreement, GeneproDx will take the lead in the development of the Idylla ThyroidPrint test, whereas Biocartis will be responsible for the distribution of the ThyroidPrint on Idylla through its growing commercial infrastructure of Idylla instruments across the globe.

Thyroid nodules are very common and are often detected during routine medical exam or by patient self-assessment. Only some 10% of fine needle aspirate (FNA) biopsy procedures1 reveal the presence of malignant cells, while approximately 70% confirm a benign (non-cancerous) diagnosis. The remaining 20% are reported as indeterminate, meaning that no certain diagnosis can be provided to physician and patients2. Annually, over 1.2 million thyroid cytology evaluations are reported as indeterminate3. In patients with such result, diagnostic surgery of the thyroid gland is frequently recommended4. The risk of malignancy in these indeterminate cases is estimated to be between 15-35%, meaning that surgical intervention is unnecessary in up to 65-85% of these cases4.

ThyroidPrint is a qRT-PCR5 based mRNA-expression classifier6 test that helps to determine whether a thyroid nodule with an indeterminate cytology result is benign or malignant7. A benign test result8 allows physicians to recommend watchful waiting as an alternative to diagnostic surgery. This prevents exposing patients to surgical risks and permanent thyroid hormone supplementation. Moreover, it significantly reduces health costs associated with unnecessary surgery3.

GeneproDxs ThyroidPrint was initially clinically validated in a multicenter trial in Chile, after which it was launched in Latin America3 in September 2018. Furthermore, the test was clinically validated in a second independent multicenter, prospective trial in the US in December 2019, demonstrating that ThyroidPrint performs in the same manner in populations with different ethnicities and genetic backgrounds9. Currently, a new international validation study is ongoing, including an estimated 200 individuals with indeterminate cytology results10, in leading academic sites in Europe, the US and Latin-America.

Herman Verrelst, Chief Executive Officer of Biocartis, commented: We are very pleased to enter into a new collaboration where a high value gene signature test is ported on Idylla. By developing an Idylla version of ThyroidPrint, GeneproDx and Biocartis may enable broad availability of this test to laboratories and hospitals around the world, to help address this high clinical unmet need in thyroid patients. For Biocartis, this also means further expansion of the oncology menu into thyroid cancer.

Hernn Gonzlez MD, PhD, Professor of Surgery at the Pontifical Catholic University of Chile and Founder of GeneproDx, reacted: As clinicians, an important challenge today is to determine whether a thyroid nodule is malignant and a patient really needs to undergo surgical resection of the thyroid gland. In our first real world clinical utility experience, ThyroidPrint revealed a meaningful impact on the physician decision by reducing diagnostic surgery by more than 70% in patients with indeterminate cytology11. We are excited to use the rapid and easy-to-use Idylla technology to develop a ThyroidPrint test that physicians can request to be performed in their local laboratories. As such, patients across the world can have the first of its kind, fast and easy-access diagnostic solution for indeterminate thyroid cytology results.

Development of the ThyroidPrint on Idylla will be initiated in Q4 2020.

--- END ---

More information: BiocartisRenate DegraveHead of Corporate Communications & Investor Relations Biocartise-mail rdegrave@biocartis.comtel +32 15 631 729 mobile +32 471 53 60 64

GeneproDxFrancisca Mena Head of Corporate Communications GeneproDxemail fmena@geneprodx.com tel +569 5608 654About Biocartis

Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis is developing and marketing a continuously expanding test menu addressing key unmet clinical needs, with a focus in oncology, which represents the fastest growing segment of the MDx market worldwide. Today, Biocartis offers tests supporting melanoma, colorectal and lung cancer, as well as tests for SARS-CoV-2 and sepsis. More information:www.biocartis.com. Follow us on Twitter: @Biocartis_.

About GeneproDx

GeneproDxs mission is to offer patients with indeterminate thyroid nodules the highest quality of precision medicine through ThyroidPrint. GeneproDxs vision is to be pioneers and leaders in the diagnosis of patients with indeterminate thyroid nodules in Latin America, through permanent innovation and the highest quality standards. GeneproDxs ThyroidPrint is the first molecular test for indeterminate thyroid nodules clinically validated in Latin America and the US. More info on http://www.thyroidprint.com.

Biocartis and Idylla are registered trademarks in Europe, the United States and other countries. The Biocartis and Idylla trademark and logo are used trademarks owned by Biocartis. This press release is not for distribution, directly or indirectly, in any jurisdiction where to do so would be unlawful. Any persons reading this press release should inform themselves of and observe any such restrictions. Biocartis takes no responsibility for any violation of any such restrictions by any person. Please refer to the product labeling for applicable intended uses for each individual Biocartis product. This press release does not constitute an offer or invitation for the sale or purchase of securities in any jurisdiction. No securities of Biocartis may be offered or sold in the United States of America absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933, as amended.

Forward-looking statementsCertain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' or managements' current expectations and projections concerning future events such as the Company's results of operations, financial condition, liquidity, performance, prospects, growth, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

1 In FNA biopsy procedures, approximately 350,000 of which are performed annually in the US alone (Popoveniuc G, Jonklaas J. Thyroid nodules. Med Clin North Am. 2012;96(2):329-349. doi:10.1016/j.mcna.2012.02.002), cells are collected from the thyroid nodule for microscopic examination

2 Faquin WC, Bongiovanni M, Sadow PM 2011 Update in thyroid fine needle aspiration. Endocrine pathology 22:178183.

3 S. Vargas-Salas et al., Genetic testing for indeterminate thyroid cytology: review and meta-analysis, 2018, Endocrine-Related Cancer, https://erc.bioscientifica.com/

4 To determine the true nature of the nodule as standard practice. Haugen BRM, Alexander EK, Bible KC, Doherty G, Mandel SJ, Nikiforov YE, Pacini F, Randolph G, Sawka A, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward D, Tuttle RMM, Wartofsky L 2015 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid: official journal of the American Thyroid Association

5 Quantitative Reverse Transcription PCR. PCR or Polymerase chain reaction is an efficient and cost-effective way to copy (amplify) small segments of DNA or RNA. As such, millions of copies of a section of DNA are made in just a few hours, allowing further analysis for clinicians to diagnose and monitor diseases using a minimal amount of sample, such as blood or tissue. Source: http://www.genome.gov, last consulted on 22 October 2020

6 Based on RTqPCR analysis, combined with an advanced machine learning algorithm

7 This means that the probability of the nodule being malignant drops from 25% to less than 5%, allowing follow-up to be recommended as an alternative to surgery. Info and source: https://thyroidprint.com/en/home-us/, last consulted on 22 October 2020

8 NPV (Negative Predictive Value) > 95%

9 M. Zafereo et al., A Thyroid Genetic Classifier Correctly predicts benign nodules with indeterminate cytology: two independent multicenter, prospective validation trials

10 Results are expected end of October 2021

11 Dominguez et al., ThyroidPrint: Preliminary Clinical Utility Experience. Archives of Endocrinol & Metab Vol 63, Suppl 02, pp 81 2019

Original post:
Press news Biocartis Group NV: Biocartis and GeneproDx To Collaborate on Fully Automated ThyroidPrint test on Idylla - GlobeNewswire

Recommendation and review posted by Bethany Smith

Nicholas C. Rohs, MD, discusses the importance of genetic testing in nonsmall cell lung cancer.

Nicholas C. Rohs, MD, assistant professor of medicine, hematology, and medical oncology, Icahn School of Medicine, Mount Sinai, discusses the importance of genetic testing in nonsmall cell lung cancer (NSCLC).

All patients with NSCLC, particularly those with lung adenocarcinoma, should undergo genetic testing, says Rohs.

An actionable mutation can be identified in about two-thirds of patients with lung adenocarcinoma, Rohs says.These actionable mutations play an important role in the treatment selection process. Oftentimes, these actionable mutations are somatic mutations rather than germline mutations, says Rohs.

Notably, several effective and well-tolerated oral therapiesare available for patients who harbor anEGFRmutation, Rohs adds.

Additionally, although it was believed that KRAS was an undruggable target,early responses with modified KRAS inhibitors have been observed in clinical trials.

The role of KRAS mutations has garnered significantexcitement in NSCLC, and is the focus of ongoing research efforts, Rohs concludes.

Read more here:
Dr. Rohs on the Importance of Genetic Testing in NSCLC - OncLive

Recommendation and review posted by Bethany Smith

November 02, 2020 -Broad-based genetic testing could identify inherited genetic mutations and accelerate precision medicine therapies for patients with cancer, according to a study published in JAMA Oncology.

Hereditary factors play a key role in the development of many cancers, researchers at Mayo Clinics Center for Individualized Medicine noted. Identifying genetic predispositions for certain cancers can have significant implications for treatment decisions, interventions, cancer screenings, and genetic testing for patients and close relatives.

Selecting patients for genetic testing has traditionally been based on pathologic features of the cancer, age at diagnosis, family history of cancer, and other factors named in clinical guidelines. Few studies have examined the impact of broad-based testing for gene mutations in patients with cancer compared with more traditional methods of selection.

Over the course of two years, Mayo Clinic researchers provided free genetic testing and counseling for 3,084 patients as part of their standard cancer care. The project included a wide range of cancer stages and types, such as breast, colorectal, lung, ovarian, pancreatic, bladder, and prostate cancers.

The results showed that with standard guidelines, physicians were only able to find 48 percent of patients with an inherited genetic mutation.

We found that 13.5 percent of patients had an inherited mutation in a gene associated with the development of their cancer, saidNiloy Jewel Samadder, MD, a Mayo Clinic gastroenterologist and hepatologist, who is the study's author.

More than half of the patients who developed cancer due to inherited mutations were being missed, and that has major implications for family members. Everyone has some risk of developing cancer, and in most cases the disease develops by chance. However, some people are genetically predisposed to developing certain types of cancer, such as breast or colon cancers.

When researchers examined the effects of a genetic mutation discovery, the team found that one-third of patients with the highest-risk cancer genes had a change in their medical management, including the type of surgery or chemotherapy they received.

This targeted treatment would have been lost if the patients had not received genetic testing, Samadder stated.

The results demonstrate the importance of genetic testing for all patients, and not just specific individuals.

Genetic testing is underutilized in cancer care, both for patients and for their families, often due to outdated guidelines that restrict testing to a narrow group of high-risk patients, saidRobert Nussbaum, MD,chief medical officer ofInvitae Corporation.

All cancer patients should have access to complete genetic information that can guide their care and inform their families' health.

Additionally, high-risk patients should share the heritable-cause of the disease with their relatives, which will allow family members to pursue disease care for earlier cancer management and detection.

We can help prevent cancer in their loved ones because it is genetic, and they share these cancer-causing genetic changes with their children, siblings and others in their families, Samadder said. We can target prevention strategies for those high-risk individuals and hopefully prevent cancer altogether in future generations of their family.

All blood-related family members of patients found to have a genetic mutation were offered free genetic testing. Overall, one in five of these family members underwent testing, the researchers said.

Going forward, the research team hopes to be able to incorporate the studys results into the care of all patients with cancer at Mayo Clinic. The study demonstrates the potential for broad genetic testing to accelerate the development of precision medicine therapies for cancer.

Steps are being taken to ensure all patients are offered genomic sequencing to better understand the genes that led to the development of their cancer, and how to precisely target treatment and improve survival, said Samadder.

Original post:
Genetic Testing Can Lead to Precision Medicine Therapies for Cancer - HealthITAnalytics.com

Recommendation and review posted by Bethany Smith

In a finding that bolsters the field of personalized medicine, a new large-scale study from the Mayo Clinic reports that one in eight cancer patients they followed had an inherited mutation that increases their risk of developing a malignancy. Further, the study showed that more than half of all patients with such mutations were being missed and therefore probably not receiving optimal treatment.

The study was carried out by scientists at Mayo Clinics Center for Individualized Medicine. They conducted genetic testing in more than 3,000 patients previously diagnosed with cancer at Mayo Clinic Cancer Center locations in Arizona, Florida, and Minnesota. Their report was published in the October 30 online edition ofJAMA Oncology. doi: 10.1001/jamaoncol.2020.6252

We found that 13.5% of patients had an inherited mutation in a gene associated with the development of their cancer, says Niloy Jewel Samadder, MD, a Mayo Clinic gastroenterologist and hepatologist, who is the studys lead author. Everyone has some risk of developing cancer, and in most cases the disease develops by chance. However, some people are genetically predisposed to developing certain types of cancer, such as breast or colon cancers.

The study confirms that nearly 10%-25% of cancer-causing mutations are inherited. It also suggests that patients with these mutations are being overlooked, when they could be candidates for targeted, or personalized, therapies drugs that act specifically against target molecules or processes that are known to cause or contribute to the development or progression of cancers.

The market for targeted cancer therapies is one of the biggest and fastest growing sectors in all of pharmaceuticals. More than a dozen such treatments are already on the market and they are often given fast-track designation as candidate drugs, which makes them particularly lucrative development projects. This market currently includes multiple drugs for both solid tumors and blood cancers, including early entrants to this market: imatinib mesylate (Gleevec), trastuzumab (Herceptin), and cetuximab (Erbitux). Findings such as this one from Mayo clinic should encourage growth and expansion of this market.

In its two-year Interrogating Cancer Etiology Using Proactive Genetic Testing (INTERCEPT) study, Mayo Clinic provided free genetic testing and counseling to 3,084 Mayo Clinic patients as part of their standard cancer care. The project, representing the largest known multicenter study of universal testing of patients with cancer, included a broad mix of cancer stages and types, including breast, colorectal, lung, ovarian, pancreatic, bladder, prostate and endometrial cancers.

The researchers were surprised to find that the standard guidelines physicians relied on to determine which patients with cancer should undergo genetic testing only identified 48% of the patients with an inherited genetic mutation.

More than half of the patients who developed cancer due to inherited mutations were being missed, and that has major implications for family members, Samadder says. Everyone has some risk of developing cancer, and in most cases the disease develops by chance. However, some people are genetically predisposed to developing certain types of cancer, such as breast or colon cancers.

During the study, the researchers found that one-third of the patients with the highest-risk cancer genes had a change in their medical management when a mutation was discovered. That change could include the type of surgery or chemotherapy they received.

This targeted treatment would have been lost if the patients had not received genetic testing, Samadder emphasizes.

Genetic testing is underutilized in cancer care, both for patients and for their families, often due to outdated guidelines that restrict testing to a narrow group of high-risk patients, says Robert Nussbaum, MD, chief medical officer of Invitae Corporation. All cancer patients should have access to complete genetic information that can guide their care and inform their families health. Nussbaum was a contributing author on the study.

Besides helping to guide optimal treatment for current patients, testing for these mutations can also benefit family members by encouraging them to undergo early detection testing and to get proper treatment if they also develop malignancies.

We can help prevent cancer in their loved ones because it is genetic, and they share these cancer-causing genetic changes with their children, siblings and others in their families, Samadder explains. We can target prevention strategies for those high-risk individuals and hopefully prevent cancer altogether in future generations of their family.

In this Mayo study, all blood-related family members of patients found to have a genetic mutation were offered free genetic testing, and one in five of those people opted for testing. The researchers say that the next steps will be to incorporate the study findings into the care of all patients with cancer at Mayo Clinic.

Read the original here:
One in Eight Cancer Patients Harbors Inherited Mutation that Increases Risk of Disease Development - Clinical OMICs News

Recommendation and review posted by Bethany Smith

Background:Emotional distress associated with genetic testing for hereditary breast and ovarian cancer syndrome (HBOC) is reported to interfere with adherence to treatment and prophylactic measures and compromise quality of life.

Objectives:To determine levels of anxiety, depression, and quality of life in patients tested for pathogenic BRCA1/2 mutations and identify risk factors for the development of adverse psycho-emotional effects.

Methods:Cross-sectional observational trial involving 178 breast or ovarian cancer patients from a referral cancer hospital in Northeastern Brazil. Information was collected with the Hospital Anxiety and Depression Scale (HADS) and the World Health Organization (WHO) Quality of Life (QoL) questionnaire (WHOQOL-BREF).

Results:Patients suspected of HBOC had higher levels of anxiety than depression. The presence of (probably) pathogenic BRCA1/2 mutations did not affect levels of anxiety and depression. High schooling, history of psychiatric disease, and use of psychotropic drugs were directly associated with high anxiety. High schooling was too inversely associated with QoL as such a breast tumor. Anxiety and depression were directly correlated and both reduced significantly QoL.

Conclusion:Our results highlight the importance of psychological support and screening of risk factors for anxiety and depression and low QoL in HBOC patients at the time of testing.

Keywords:Anxiety; Breast cancer; Depression; Hereditary breast and ovarian carcinoma syndrome; Quality of life.

Read the original here:
How does genetic testing influence anxiety, depression, and quality of life? A hereditary breast and ovarian cancer syndrome suspects trial - DocWire...

Recommendation and review posted by Bethany Smith

President Trumps illness from a coronavirus infection last month was the most significant health crisis for a sitting president in nearly 40 years. Yet little remains known about how the virus arrived at the White House and how it spread.

The administration did not take basic steps to track the outbreak, limiting contact tracing, keeping cases a secret and cutting out the Centers for Disease Control and Prevention. The origin of the infections, a spokesman said, was unknowable.

But one standard public health technique may still shed some light: tracking the clusters genetic fingerprints.

To better understand the outbreak, The New York Times worked with prominent geneticists to determine the genetic sequence of viruses that infected two Times journalists believed to have been exposed to the coronavirus as part of their work covering the White House.

The study reveals, for the first time, the genetic sequence of the virus that may have infected Mr. Trump and dozens of others, researchers said. That genome is a crucial clue that may allow researchers to identify where the outbreak originated and whether it went on to infect others across the country.

The White House has not disclosed any effort to conduct similar genetic testing, but the studys results show that it is still possible, even weeks after positive tests. Additional sequencing could help establish the path of the virus through the White House, the role of a possible super-spreading event for Judge Amy Coney Barrett and the origin of an outbreak among the staff of Vice President Mike Pence in the last week or so.

The journalists, Michael D. Shear and Al Drago, both had significant, separate exposure to White House officials in late September, several days before they developed symptoms. They did not spend any time near each other in the weeks before their positive tests.

Mr. Shear traveled with Mr. Trump and other staff on Air Force One on Sept. 26, when Mr. Trump approached within five or six feet without a mask. Mr. Drago covered the Judge Barrett event that day and a news conference the next day near officials who were not wearing masks and later tested positive. Both journalists wore masks.

The viral genomes of the two journalists shared the same distinct pattern of mutations, the research found. Along with their exposure history, the findings suggest that they were infected as part of the broader White House outbreak, said Trevor Bedford, a geneticist at the Fred Hutchinson Cancer Research Center and the University of Washington who led the research team.

These mutations that are possessed by these viruses are quite rare in the United States, Dr. Bedford said. I am highly convinced that these viruses come from the same outbreak or cluster based on their genomes.

The study, which has been posted online but not yet peer reviewed or published in a science journal, followed academic protocols that require genetic samples to be anonymous. Mr. Shear and Mr. Drago chose to disclose their identities for this article.

Viruses constantly mutate, picking up tiny, accidental alterations to their genetic material as they reproduce. Few mutations alter how a virus functions. But by comparing patterns of mutations across many genetic sequences, scientists can construct family trees of a virus, illuminating how it spreads.

The genomes believed by these researchers to be connected to the White House outbreak do not identify a recent geographic source, in part because they are unusual. The ancestors of those viruses spread to the United States from Europe and were circulating widely across the country in April and May, but the trail goes cold after that, according to Dr. Bedford.

Geneticists said the genomes are a key piece of the puzzle that may spur future research to determine where the White House outbreak originated and where it may go next. Scientists collect and publish tens of thousands of new sequences of the coronavirus every month, and additional testing may fill in the picture.

The results show that even weeks after it was identified, the White House outbreak would be better understood by sequencing samples of more people who were infected. Swabs used in positive tests are often kept in labs for months after an initial infection, and genetic material for the coronavirus is stable if stored appropriately.

The C.D.C. routinely relies on genetic testing to help understand Covid-19 outbreaks elsewhere across the country. In a study released on Thursday, the C.D.C. cited genetic sequencing and intensive contact tracing that documented an super-spreading event at a high school retreat in Wisconsin.

But the Trump administration is not known to have conducted its own genetic analysis of people infected in the outbreak. The White House declined to respond to questions on genetic sequencing of Mr. Trump and the cluster of aides and officials who tested positive or became ill.

There is still a remote possibility, Dr. Bedford said, that a previously unseen version of the virus had been circulating undetected in Washington or Northern Virginia and infected both journalists independently from the White House cluster. More testing of the outbreak could eliminate that possibility entirely, he said.

Scientists not involved in the research who reviewed the results agreed with the conclusion that the two samples sharing rare mutations strongly suggested they are part of the same outbreak.

These genomes are probably going to be identical or nearly identical to the genome that infected the president, said Michael Worobey, head of the department of ecology and evolutionary biology at the University of Arizona.

Dr. Worobey disputed the White Houses characterization that the source of the outbreak could not be known.

A lot of things are unknowable if you make no effort to know anything about them, and this falls into this category, Dr. Worobey said. All of these things actually can be known if you make the effort and you have the transparency that scientists are desperately trying to promote as we sequence hundreds of thousands of these genomes around the world.

For months, the White House minimized the threat of the virus and eschewed basic safety precautions at official events, like wearing a mask or keeping people six feet apart.

At least 11 people who attended a Rose Garden celebration on Sept. 26 for Judge Barrett, which included an indoor event without masks, became infected with the coronavirus, including Mr. Trump. Additional genetic testing could help more clearly establish the role of that event.

Dr. Bedford and his colleagues were able to obtain a full genetic sequence for the virus that infected Mr. Shear and a partial sequence of the virus that infected Mr. Drago. Several unusual mutations matched in the two samples, sufficient evidence to determine with a very high probability that they were essentially the same genome, Dr. Bedford said.

The work was carried out by a multidisciplinary team of researchers at the University of Washington School of Medicine, the Hutchinson Center and the Brotman Baty Institute for Precision Medicine in Seattle.

The work is convincing, and it is the best way to piece together the progression of such an outbreak, said David Engelthaler, head of the infectious disease branch of the Translational Genomics Research Institute in Arizona, where he and colleagues have sequenced thousands of genomes to track the spread of the coronavirus, including devastating outbreaks at Native American reservations in the state.

Its critical no matter where we are to sequence this virus, Dr. Engelthaler said. Not just at the White House, but at the White Mountain Apache Reservation here in Arizona.

Carl Zimmer contributed reporting.

Read this article:
Tests Show Genetic Signature of Coronavirus That Likely Infected Trump - The New York Times

Recommendation and review posted by Bethany Smith

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Rare Disease Genetic Testing market.

Trusted Business Insights presents an updated and Latest Study on Rare Disease Genetic Testing Market 2020-2029. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Rare Disease Genetic Testing market during the forecast period (2020-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Rare Disease Genetic Testing Market 2020 and Forecast 2021-2027 Includes Business Impact Analysis of COVID-19

Report Overview: Rare Disease Genetic Testing Market

The global rare disease genetic testing market size was valued at USD 690.1 million in 2020 and is projected to register a Compound Annual Growth Rate (CAGR) of 8.8% from 2021 to 2027. Misdiagnosis can result in interventions that could later be considered inappropriate for the underlying disorder. Thus, the need for an accurate and timely diagnosis for rare conditions drives the demand for genetic testing. Currently, the lack of awareness pertaining to these conditions is one of the primary challenges for the market. Thus, several efforts are being undertaken to help raise awareness about various aspects of rare and ultra-rare diseases, such as the challenges pertaining to diagnosis and clinical implementation of available diagnostic approaches.

Companies like Shire Plc are engaged in supporting domestic diagnostic testing for rare disorders in certain countries and offer learning programs for healthcare experts on genetic testing. Every country has developed its registry for rare diseases that acts as a focal point of information on these conditions. Patient registries and databases play a integral role in clinical research in the field of rare diseases and help in improving healthcare planning and patient care.

A rise in the number of available registries is one of the major driving factors of the market as it enables pool data to achieve a sufficient sample size for epidemiological and/or clinical research. Furthermore, technological advancements in data collection and interpretation for clinical practice has driven the market. Companies are making efforts to ensure efficient data collection from various ethnicities, which is expected to aid in the diagnosis of thousands of patients with the same condition.

In addition, companies, such as Centogene, combine genetic testing with metabolomics and proteomics to make their data analysis process as accurate as possible. The multi-omics approach helps better understand the impact of a given mutation on the protein as well as at the metabolite level. The company has also introduced a system to simplify the sample collection process, thereby driving the adoption of genetic tests for rare disease diagnosis.

Disease Type Insights: Rare Disease Genetic Testing Market

Neurological disorders segment accounted for the largest share of 12.9% in 2019. A substantial number of commercially-approved genetic tests for neurologic conditions coupled with a high prevalence of neurological diseases has accelerated the revenue growth in this segment. Tests offered by companies are recommended by several medical institutes, such as the American Academy of Neurology, American College of Medical Genetics, and Child Neurology Society.

Furthermore, the advent of high-throughput techniques, such as exome sequencing and whole-genome sequencing, has offered lucrative opportunities for companies offering tests for diseases, such as X-ALD. Exome sequencing and whole-genome sequencing have helped in addressing complicated cases of X-ALD that present an atypical disease course.

Moreover, immunologic disorders, such as Multiple Sclerosis (MS), are among the most prevalent rare diseases. The genetic profile of MS is one of the key focus areas among researchers in this field. This is primarily to obtain relevant insights pertaining to the causes and underlying physiology of diseases, resulting in a significant share of this segment.

End-use Insights: Rare Disease Genetic Testing Market

Research laboratories & CROs captured the maximum share of 46.9% of the market in 2019. This is primarily because in a substantial number of cases, blood samples collected from patients are sent to a laboratory for testing. Laboratories offer testing based on various specialties, including molecular, chromosomal, and biochemical genetic tests. For instance, ARUP Laboratories offers testing in molecular genetics, cytogenetics, genomic microarray, and biochemical genetics.

Laboratories also offer genetic counseling services that further accelerate the uptake of services among patients. Moreover, molecular genetic testing-based laboratory testing is rapidly increasing worldwide. Genetic tests are conducted by multiple laboratories, including those that are accredited with CLIA for clinical cytogenetics, pathology, and chemistry, among other specialties. These companies are involved in expanding their test portfolio by undertaking various strategic initiatives.

For instance, in January 2020, Quest Diagnostics acquired Blueprint Genetics to enhance its expertise in genetic disorders and rare diseases. Furthermore, in June 2018, Centogene launched its diagnostic laboratory in Cambridge, Massachusetts. Such initiatives depict the growing interest of diagnostic centers in genetic testing of rare diseases, which is likely to boost segment growth.

Technology Insights: Rare Disease Genetic Testing Market

Next Generation Sequencing (NGS) accounted for the largest share of 36.6% in 2019 owing to the high usage of Whole Exome Sequencing (WES). WES is being considered a highly potential method in a case where the genetic cause of disease is unknown and is difficult to identify. WES is becoming the standard of care for patients with undiagnosed rare diseases. This is attributed to the fact that exons make up around 1.5% of an individuals genome and contain 85% of all known disease-causing mutations.

Moreover, with the declining costs of WES, the cost of genetic testing is also anticipated to reduce significantly, making the test more affordable and accessible. In addition, medical coverage for WES-based genetic tests has favored segment growth. A substantial number of private health insurance agencies cover all or part of the cost of genetic testing, post recommendation by a healthcare professional. As compared to WES, clinical Whole Genome Sequencing (WGS) has lesser demand.

However, with a continuous decrease in cost, adoption of WGS is expected to amplify. For instance, the Rady Childrens Institute for Genomic Medicine offers singleton-rapid WGS and a trio-rapid WGS at a reasonable cost. In February 2020, Dante Labs launched an initiative to offer WGS to patients with rare diseases for USD 299. The service included WGS 30X on Novaseq6000 technology, data interpretation, and personalized therapy on these diseases.

Specialty Insights: Rare Disease Genetic Testing Market

Accounting for more than 40% revenue share, molecular genetic tests led the market in 2019. Rapid technological advancements and expertise in handling & managing high throughput technologies within clinical settings have driven the revenue in this segment. Molecular genetic test methods enable investigating single genes or short lengths of DNA for the detection of mutations or variations leading to genetic disorders.

Apart from rare diseases, the method also covers testing of ultra-rare diseases, which will augment the segment growth in future. Biochemical genetic tests are expected to register the second-fastest CAGR during the forecast period owing to their efficiency to assess the activity and amount of proteins & related abnormalities for the identification of changes in the DNA that can cause a metabolic disorder.

Also, the companies are expanding their test portfolio to capitalize on the potential opportunities present in this segment. In September 2019, Blueprint Genetics collaborated with ARCHIMEDlife to launch high-quality biochemical tests for rare diseases. Such developments are anticipated to boost the revenue share of the segment in the coming years.

Regional Insights: Rare Disease Genetic Testing Market

North America accounted for the largest market share of over 47% in 2019. Factors, such as high incidence of rare disorders, a large number of rare disorders registries, and the presence of substantial numbers of R&D facilities for rare & ultra-rare diseases, and extensive investments in the diagnosis of rare disorders in the region drives the market growth. As per the National Institutes of Health (NIH), around 30 million Americans have been identified with one of 7,000+ known rare diseases. Moreover, the number of patients undergoing disease testing is expected to increase in the coming years, thereby supporting market growth.

Asia Pacific is expected to register the fastest CAGR from 2020 to 2027 due to rising awareness and target population in Asian countries. China is attempting to shift the attention of the healthcare system towards the diagnosis and treatment of rare disorders. The government in the country has included rare disease management as a public health priority in its 2030 roadmap titledHealthy China 2030. Furthermore, in June 2018, the country released its first list of rare disorders to enable the patients to find solutions effectively at their local hospitals.

Key Companies & Market Share Insights: Rare Disease Genetic Testing Market

The development of technologies, such as WES & WGS, has significantly transformed genetic testing space by offering convenient and cost-effective methods that can be conducted for a wide range of conditions across multiple clinical settings. As a result, major diagnostic companies are engaged in expanding their product portfolio that can be used to conduct tests for rare and ultra-rare conditions.

In addition, they have undertaken various initiatives, such as mergers & acquisitions, to expand their offerings and subsequently strengthen their presence in this market. For example, the acquisition of GeneDX by OPKO. The acquisition helped the latter company to expand its business in the market. Similarly, Quest strengthened its presence in the market with the acquisition of Blueprint Genetics. Another important acquisition in the market is Qiagens acquisition by Thermo Fisher.

The companies have signed an agreement in March 2020; however, it is targeted to be completed by the first quarter of 2021, as ThermoFisher Scientific is lining up finances for the USD 11.5 billion deal, with an offering worth $2.2 billion. This deal is expected to impact the life science tools and reagents market significantly. With regard to rare disorder genetic testing, Thermo Fisher Scientific is engaged in research and provides sequencing for the Osteogenesis imperfecta and Vascular Ehlers-Danlos syndrome. Some of the prominent players in the rare disease genetic testing market include:

Key companies Profiled: Rare Disease Genetic Testing Market Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub segments from 2016 to 2027. For the purpose of this study, Trusted Business Insights has segmented the global rare disease genetic testing market report on the basis of disease type, technology, specialty, end use, and region:

Disease Type Outlook (Revenue, USD Million, 2016 2027)

Technology Outlook (Revenue, USD Million, 2016 2027)

Specialty Outlook (Revenue, USD Million, 2016 2027)

End-use Outlook (Revenue, USD Million, 2016 2027)

Looking for more? Check out our repository for all available reports on Rare Disease Genetic Testing in related sectors.

Quick Read Table of Contents of this Report @ Rare Disease Genetic Testing Market 2020 and Forecast 2021-2027 Includes Business Impact Analysis of COVID-19

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

Read the original:
Rare Disease Genetic Testing Market 2020 and Forecast 2021-2027 Includes Business Impact Analysis of COVID-19 - Eurowire

Recommendation and review posted by Bethany Smith

The Global Direct-to-Consumer Genetic Testing Market Report, published by Emergen Research, offers a complete assessment of the major segments of the global Direct-to-Consumer Genetic Testing market, estimating the market growth rate over the forecast timeline (2020-2027). The latest research report can be viewed as a valuable source of data and information about this particular business sphere. Our team of market experts has performed a thorough future market growth analysis and assessed the demand & supply graphs and the markets historical and future revenue generation. The report is equipped with a vivid description of the current trends of the global Direct-to-Consumer Genetic Testing market. It holds an unbiased perspective of the leading market players, intense competition, the major regions/countries, end-use industries, and a broad continuum of products available in this market. Therefore, the market intelligence report offers a 360 view of the global Direct-to-Consumer Genetic Testing industry and provides significant information pertinent to the various growth-inducing and growth-restraining factors in detail.

The latest study unravels the unfavorable impacts of the COVID-19 pandemic on the global Direct-to-Consumer Genetic Testing business sector. According to our expert team, the corona virus outbreak has had an overwhelming impact on the global economic landscape, and consequently, on this business vertical. The pandemic is expected to contribute to the potential downturn of the Direct-to-Consumer Genetic Testing industry substantially. Reportedly, this sector has been financially beleaguered since the COVID-19 lockdown restrictions were put into effect. Hence, the report highlights the financial obstacles that have slowed numerous businesses progress in this sector and disrupted the global supply chains.

Request a sample copy of the Direct-to-Consumer Genetic Testing market report @ https://www.emergenresearch.com/request-sample-form/20

Competitive Overview:

The global Direct-to-Consumer Genetic Testing market report closely studies the functioning mechanisms of the key companies participating in the global market. These companies are said to be following a slew of business expansion strategies to reinforce their financial positions in this market. As per the report, these companies account for a major portion of the overall Direct-to-Consumer Genetic Testing market share. Therefore, this section of the report emphasizes the principal strategic initiatives led by these companies, including mergers & acquisitions, joint ventures, new business deals, new product launches, collaborations, technological upgradation, and several others.

Key Market Players:

23andMe, Full Genome Corporation, Color Genomics, Genesis Healthcare, Helix OpCo LLC, FamilyTreeDNA, MyHeritage, Identigene, Pathway genomics, and Living DNA

Emergen Research has segmented the global Direct-to-Consumer Genetic Testing Market on the basis of Test Type Outlook, Distribution Channel Outlook, Application Outlook, and region:

Geographical Terrain of the Direct-to-Consumer Genetic Testing Market:

To get a discount on the report, click on the link here: @ https://www.emergenresearch.com/request-discount-form/20

Global Direct-to-Consumer Genetic Testing Market Report Table of Contents:

1.1 Research Scope

1.2 Key Direct-to-Consumer Genetic Testing market segments

1.3 Target players

1.4 Market analysis by type

1.5 Market analysis by application

1.6 Key learning objectives

1.7 Report timeline

2.1 Global Direct-to-Consumer Genetic Testing market size

2.2 Latest trends of the Direct-to-Consumer Genetic Testing market by region

2.3 Key corporate trends

3.1 Global Direct-to-Consumer Genetic Testing Market size by manufacturers

3.2 Global Direct-to-Consumer Genetic Testing Market key players

3.3 Products/solutions/services of major players

3.4 New entrants in the Direct-to-Consumer Genetic Testing market

3.5 Mergers, acquisitions, joint ventures, and expansion plans

4.1 Global Direct-to-Consumer Genetic Testing Sales by Product

4.2 Global Direct-to-Consumer Genetic Testing by Product Revenue

Request a customized copy of the report @ https://www.emergenresearch.com/request-for-customization-form/20

Key highlights of the report:

Download the full Direct-to-Consumer Genetic Testing market description @ https://www.emergenresearch.com/industry-report/direct-to-consumer-genetic-testing-market

Thank you for reading our report. For further details or to inquire about customization, please let us know, and we will offer you the report well-suited to your requirements.

About Emergen Research

At Emergen Research, we believe in advancing with technology. We are a growing market research and strategy consulting company with an exhaustive knowledge base of cutting-edge and potentially market-disrupting technologies that are predicted to become more prevalent in the coming decade.

Our expertise umbrellas the technological environment of all major industries, and our services help you map your actions to ensure optimal yield. Our analysts utilize their market proficiency to offer actionable insights that help our clients implement profitable strategies and optimize their return on investment. Our services are wide-ranging, right from technological environment analysis to technological profiling that highlights the existing opportunities in the market you can capitalize on to stay ahead of your competitors.

Contact Us:

Eric Lee

Corporate Sales Specialist

14671 110 Avenue, Surrey, British Columbia, V3R2A9

Emergen Research | Web: https://www.emergenresearch.com

E-mail: [emailprotected]

See the rest here:
Direct-to-Consumer Genetic Testing Market Strategic Insights 2020 with analysis of Leading Players: 23andMe, Full Genome Corporation, Color Genomics,...

Recommendation and review posted by Bethany Smith

The global Direct-to-consumer Genetic Testing market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 15.0% in the forecast period of 2020 to 2025 and will expected to reach USD 2277.9 million by 2025, from USD 1301.3 million in 2019.

Direct-to-consumer Genetic Testing Market report covers the present and past market scenarios, market development patterns, and is likely to proceed with a continuing development over the forecast period. The research report on Direct-to-consumer Genetic Testing Market provides comprehensive analysis on market status and development trend, including types, applications, rising technology and region. A number of analysis tools such as SWOT analysis and Porters five forces analysis have been employed to provide an accurate understanding of this market.

Some of the key players of Direct-to-consumer Genetic Testing Market:23andMe, DNA Diagnostics Center, Myriad Genetics, MyHeritage, Gene By Gene, LabCorp, IntelliGenetics, Quest Diagnostics, Ancestry.com, Invitae, Centrillion Technology, Anglia DNA Services, Ambry Genetics, Canadian DNA Services

Get Sample Copy of this Report @https://www.reportsweb.com/inquiry&RW00013143599/sample

The Global Direct-to-consumer Genetic Testing Market research report offers an in-depth analysis of the global market, providing relevant information for the new market entrants or well-established players. Some of the key strategies employed by leading key players operating in the market and their impact analysis have been included in this research report.

Segmentation by product type:

Segmentation by application:

Get Discount for This Report @https://www.reportsweb.com/inquiry&RW00013143599/discount

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Direct-to-consumer Genetic Testing market based on product and application. It also provides market size and forecast till 2025 for overall Direct-to-consumer Genetic Testing market with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America (SAM), which is later sub-segmented by respective countries and segments.

Fundamentals of Table of Content:

1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered1.4 Market Analysis by Type1.5 Market by Application1.6 Study Objectives1.7 Years Considered

2 Global Growth Trends2.1 Direct-to-consumer Genetic Testing Market Size2.2 Direct-to-consumer Genetic Testing Growth Trends by Regions2.3 Industry Trends

3 Market Share by Key Players3.1 Direct-to-consumer Genetic Testing Market Size by Manufacturers3.2 Direct-to-consumer Genetic Testing Key Players Head office and Area Served3.3 Key Players Direct-to-consumer Genetic Testing Product/Solution/Service3.4 Date of Enter into Direct-to-consumer Genetic Testing Market3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product4.1 Global Direct-to-consumer Genetic Testing Sales by Product4.2 Global Direct-to-consumer Genetic Testing Revenue by Product4.3 Direct-to-consumer Genetic Testing Price by Product

5 Breakdown Data by End User5.1 Overview5.2 Global Direct-to-consumer Genetic Testing Breakdown Data by End User

Purchase This Report @https://www.reportsweb.com/buy&RW00013143599/buy/3480

About ReportsWeb:ReportsWeb.comis a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.

Contact Us:Call: +1-646-491-9876Email:[emailprotected]

See the rest here:
Know more about- How Direct-to-consumer Genetic Testing Market is Bringing New Innovation in Upcoming Years| Myriad Genetics, MyHeritage, Gene By...

Recommendation and review posted by Bethany Smith

Direct-Access Genetic Testing Market Size And Forecast

Market Research Intellect has newly added an informative report on the Direct-Access Genetic Testing Market to its large volume of database. This research report sheds light on various attributes of the global market such as present scenario, historical developments and upcoming trends to understand the market clearly. This analytical market research reports a 360-degree overview of the Direct-Access Genetic Testing Market that offers massive data by analyzing the latest market trends, innovative platforms, tools, technologies and global market growth opportunities. Different global market dynamics such as market drivers, restraints, threats, risks, challenges and opportunities have been mentioned in the report. This analytical report will help both established companies and new entrants to identify the consumers demands, current market needs, market size and global competition among leading key players.

Regional outlook:

The Direct-Access Genetic Testing Market has been examined into various global regions such as North America, Latin America, Middle East, Asia-pacific, Africa and Europe based on various perspectives like type, applications, market size, etc. North America is leading the market position in Direct-Access Genetic Testing Market over the forecast period. Furthermore, Asia-Pacific region is marking and impressive growth for the Direct-Access Genetic Testing Market.

A notable feature of this innovative market research report is, it comes with detailed analysis on, impact of covid-19 on Direct-Access Genetic Testing Market growth. The viral outbreak of COVID-19 (Corona Virus) across the global regions led to a sudden pause in production and manufacturing activities in various business sectors. Moreover, rising stringent rules and regulations imposed by the government on industrial sector are also affecting the production capabilities for the Direct-Access Genetic Testing Market. Due to the disruption to the manufacturing process and push-out of global customer orders, the market is getting affected presently. We at Market Research Intellect, offer insight views on the Direct-Access Genetic Testing Market for making strategic business decisions over the forecast period.

Competitive Landscape:

A competitive landscape of the Direct-Access Genetic Testing Market has been presented by examining numerous leading companies functioning across the leading global regions. Moreover, it sheds light on various attributes such as company overview, contact information, product overview, financial overview, marketing methodologies and distribution channels.

Following key players have been profiled with the help of proven research methodologies:

Direct-Access Genetic Testing Market Segmentation:

Direct-Access Genetic Testing Market Segment by Type:

Direct-Access Genetic Testing Market Segment by Application:

Direct-Access Genetic Testing Market Segment by Global Presence:

North America Latin America Middle East Asia-Pacific Africa Europe

The report has been aggregated by using a couple of research methodologies such as primary and secondary research techniques. It helps in collecting informative pieces of professional information for deriving effective insights into the market. This informative report helps in making well informed and strategic decisions throughout the forecast period.

Key questions answered through this analytical market research report include:

What is the Direct-Access Genetic Testing Market? What are the primary factors boosting the Direct-Access Genetic Testing Market? What will be the Direct-Access Genetic Testing Market size and the growth rate over the forecast period? What are the outcomes of SWOT and Porters five forces in market growth? What are the demanding regions across the globe? What are the challenges, threats and risks faced by new entrants in the market? What are the global market growth opportunities in front of the market growth? Which factors are responsible for hampering the market growth? What are the latest trends in the market? What are the recent industry developments in Direct-Access Genetic Testing Market?

If you have any custom requirements, please let us know and we will offer you the customized report as per your requirements.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Website https://www.marketresearchintellect.com/

See the original post:
Direct-Access Genetic Testing Market Size to receive overwhelming hike in Revenues by 2020 2027 - Eurowire

Recommendation and review posted by Bethany Smith

With the rise of actionable mutations in lung cancer, the role of molecular testing has become increasingly important, according to Tony S. K. Mok, MD, BMSc, FRCPC, FASCO, and as more targeted agents emerge in the treatment landscape, the results from these tests must be used to inform clinical decisions.

Molecular testing to find a targetable mutation is already an important part of our daily practice. However, the process of finding these mutations may not be easy, said Mok. I believe we have a moral obligation to give it our best try. We need to obtain the best tissue or blood sample [that we can] and then use molecular testing to [identify] whether an oncogene driver [is present] so that we can select the appropriate treatment for each patient.

In an interview with OncLive, Mok, chairman of the Department of Clinical Oncology and Li Shu Fan Professor of Clinical Oncology at The Chinese University of Hong Kong, discussed the actionable mutations that have been identified in the lung cancer space, the agents that have been developed to target them, and the importance of genetic testing to provide personalized care.

Mok: In the EGFR-mutant lung cancer space, we have 3 generations of therapies available. First-generation agents include erlotinib (Tarceva) and trametinib (Mekinist). Second-generation agents include afatinib (Gilotrif) and dacomitinib (Vizimpro). Finally, we have the third-generation agent, osimertinib. Each of these agents have their own set of special features; however, we now must determine whether there is one subgroup that may benefit more from one particular therapy than the others. For example, its understood that osimertinib may have superiority in patients who have brain metastases.

If there was an Oscar Award for the arena of lung cancer in 2020, then it would probably go to the ADAURA trial. This study was published in The New England Journal of Medicine and reported the use of osimertinib in the adjuvant setting for patients with resectable EGFR-mutant NSCLC.

The primary end point of the trial was disease-free survival (DFS) in patient with stage II/IIIa disease. There was a hazard ratio of 0.17. Now, with the DFS and impressive hazard ration, there is a reasonable chance that it may translate into an overall survival (OS) benefit.

I believe that every patient with resectable EGFR-mutant lung cancer should be informed about the study. The question of whether we should wait for OS data is debatable. However, the way I see it is, if a patient doesnt know about this [potential option], then they dont have a choice. What would happen if we do end up finding an OS benefit years later, but we had not informed our patients? This is an important study and our patients should be informed about it.

In the upcoming years, I believe that will be the focus of many efforts: the management of osimertinib (Tagrisso) resistance. As demonstrated during the 2020 ASCO Virtual Scientific Program and the 2020 ESMO Virtual Congress, there have been several exciting advancements.

For example, there is the use of bispecific antibodies that target both EGFR and MEK mutations. When [amivantamab (JNJ-61186372; JNJ-6372) was] used with lazertinib, there is a response rate of about 36%, which is encouraging for patients who have already [progressed on] osimertinib.

The other approach is to use an antibody-drug conjugate [ADC]. Another report from ESMO looked at the use of patritumab deruxtecan [U3-1402], which is an ADC that targets HER3; this agent also demonstrated a response of about 25%. I believe theres a lot of room for development when it comes to using different modalities to target patients who are resistant to osimertinib.

In terms of BRAF mutations, its quite standard to use the combination of trametinib and dabrafenib (Tafinlar) in patients with BRAF V600Epositive disease, either in the first- or second-line setting. [Its also important to remember the] resistance mechanism that has been reported [with this approach].

We have also seen exciting data in terms targeting ALK mutations. Two new compounds have been explored in phase 3 studies that turned out to be positive. For example, the CROWN study evaluated the role of first-line lorlatinib (Lorbrena), the central nervous system efficacy that we saw, and how the use of this agent compares with other second-generation TKIs.

With regard to ROS1, beyond crizotinib (Xalkori), theres entrectinib (Rozlytrek) and erlotinib. [We are examining] what the role of these agents will be in the management of ROS1-positive lung cancer.

Crizotinib was evaluated in about 50 patients who harbored ROS1 mutations, and we saw a high response rate of about 72% and a PFS of about 19 months. Stepping into the present, there are now additional studies to consider.

Lorlatinib was also able to target ROS1 and was included in the report by Benjamin Solomon, MD, of Peter MacCallum Cancer Centre, and colleagues, were also able to demonstrate a high efficacy, as well. Even after [progressing on] crizotinib, there was a response rate of over 30% [with this agent]. Entrectinib (Rozlytrek) is also used to ROS1 and has been associated with a high response rate.

BRAF V600E in a driver oncogene, which we know from melanoma. However, this could also occur in lung cancer, in about 3% of patients. Why V600E? Its because this transformation will add on to the growth signal that is actually controlled by the BRAF pathway. To adequately inhibit this [mutation, we needed] dual targeting.

As such, trametinib plus dabrafenib has been shown to be better than dabrafenib monotherapy. Now, [with this approach], there is an associated response rate of 60%, in the first- or second-line settings, and the median PFS is about 10 months. We should not miss the opportunity to identify a BRAF mutation, because patients can benefit from this inhibition.

Molecular testing has become a standard of care. The first target [that was discovered was] EGFR but, in a relatively short time, we were able to identify ALK and ROS1. As such, [those targets] have now become a part of daily practice, as well.

However, it doesn't stop there. There are also BRAF V600E and MET 14 skipping mutations. In the future, we could potentially target HER2, RET, and NTRK in this space. Instead of testing just one [mutation] at a time, we could test for all of them from the start.

There is still some debate around who should receive next-generation sequencing (NGS) early on; however, in the United States, its common for patients with lung cancer to undergo NGS from the start, before treatment initiation.

Read this article:
Efforts to Target Actionable Alterations in Lung Cancer Abound, Emphasizing Need for Testing - OncLive

Recommendation and review posted by Bethany Smith